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Abstract 
Peptides are involved in many physiological processes such as regulation of blood-pressure, 
food intake, pain transmission and blood-glucose levels. They consist of amino acids that are 
connected through amide bonds which make peptides hydrophilic and conformationally 
flexible. Peptides generally make poor oral drugs as amide bonds are easily cleaved by 
endogenous enzymes. One way to overcome the structural problems with peptides is to 
develop stabilized mimetics, so called peptidomimetics, via a scaffold approach. The amino 
acid side chains needed for activity are attached as substituents to the scaffold.  
In this thesis, chroman-4-ones and chromones have been used as scaffolds for the 
development of peptidomimetics. These frameworks are naturally occurring derivatives 
containing an oxa-pyran ring. Depending of the substitution pattern they show different 
biological effects. Synthetic modifications in the 2-, 3-, 6-, and 8-positions of chromones and 
chroman-4-ones have been conducted. This work has included the development of an 
efficient synthetic route to obtain 2-alkyl chroman-4-one derivatives. Via bromination in the 
3-position of chroman-4-one, various substituents (NH2, Br, OAc, CN, CH2NHCbz) have 
been introduced either through substitution reactions or via a Sm-mediated Reformatsky 
reaction. By incorporation of the appropriate substituents on the chromone-4-one and the 
chromone scaffolds, the biological applications have included the development of β-turn 
mimetics of the peptide hormone somatostatin. This has resulted in two compounds with 
agonistic properties for two subtypes of somatostatin receptors. 
In addition, functionalized 2-alkyl substituted chroman-4-one and chromone derivatives 
were developed as selective inhibitors of the Silent information type 2 (Sirt2) enzyme. Sirt2 
functions as a deacetylating enzyme using both histones and non-histone proteins (e.g. α-
tubulin) as substrates. Sirt2 is located in the cytosol but enters the nucleus during mitosis. 
Evaluation of a number of chroman-4-one and chromone derivatives resulted in the 
identification of a series of novel Sirt2-selective inhibitors with IC50 values in the low µM 
range. Two chroman-4-one derivatives with 2-pyridylethyl substituents in the 2-position of 
the chroman-4-one showed significant reduction of the proliferation of breast and lung 
cancer cells using a fluorescent based assay. These results indicate that the synthesized 
chroman-4-one based Sirt2-selective inhibitors can be valuable in more detailed studies of 
the function of Sirt2 in cancer. 
 
Keywords: Chroman-4-ones, Chromones, Inhibitors, Molecular Modeling, Peptidomimetic, 
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1. Introduction 
 
1.1 Bioactive peptides  
Peptides are involved in a wide range of biological processes, e.g. regulation of blood 
pressure, food intake, pain transmission, and blood-glucose levels. Peptides consist of amino 
acids linked together via amide bonds (Figure 1).1 There are 20 naturally occurring amino 
acids with side chains comprising both hydrophilic and hydrophobic groups. The 
combinations of amino acids with different side chains provide peptides with high structural 
variation and diverse biological functions. Several endogenous bioactive peptides have been 
identified such as vasopressin,2 oxytocin,3 enkephalin,4 insulin,5, 6 somatostatin,7 and 
angiotensin II.8 A peptide adopts its bioactive conformation upon binding to its target. It 
can then activate/deactivate the target, e.g. a G-protein coupled receptor (GPCR) or an 
enzyme.  
 
Figure 1. The primary structure of a peptide is defined by the order of the amino acids linked 
together via amide bonds.  
Peptides interact with their targets via ionic and hydrogen bonds, π-π interactions, and van 
der Waal’s interactions. The flexibility and the propensity to form intramolecular hydrogen 
bonds allow peptides to adopt secondary structures such as turns, sheets, and helices. 
Peptide turns, comprising α-, β-, and γ-turns, function as recognition sites when peptides 
bind to their target receptors.9 The β-turn is the most prevalent secondary structure of 
peptides, classified according to  and ψ torsion angles of amino acids i+1 and i+2. β-Turns 
are denoted type I, I´, II, II´ III, and VIII,10-13 the type II β-turn (Figure 2) is defined by 
(i+1)= –60°, ψ(i+1)= –30°, (i+2)= –120° and ψ(i+2)= 120° and is of particular interest in 
this thesis.  
 
Figure 2. A β-turn is formed by a tetrapeptide fragment and functions as a recognition site 
between a peptide and its receptor. The turn is defined by  and ψ angles. 
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1.1.1 Peptides as drugs and development of peptidomimetics 
There are limitations for using peptides as oral drugs due to their physico-chemical 
properties such as high polarity and high conformational flexibility. In addition, peptides 
undergo rapid enzymatic degradation by cleavage of the amide bonds. These structural 
properties contribute to short half-life, low bioavailability, and lack of selectivity. However, 
peptides are still possible to use as drugs, this can be exemplified by the macromolecules 
insulin (blood glucose regulator), cyclosporin A (immunosuppressant), and oxytocin (smooth 
muscle contractile agent). With the exception of cyclosporin A, which is used as a peroral 
drug, insulin and oxytocin are intravenously administered due to the instability of the drugs 
in the gastro-intestinal (GI) tract.  
The development of conformationally restricted analogs of peptides has been a successful 
approach in terms of improving selectivity and chemical stability of peptides towards 
enzymatic degradation. Such peptide mimicking agents are termed peptidomimetics.14-18 The 
International Union of Pure and Applied Chemistry (IUPAC) has stated the following 
definition for peptidomimetics; ”A peptidomimetic is a compound containing non-peptidic structural 
elements that is capable of mimicking or antagonizing the biological action(s) of a natural peptide. A 
peptidomimetic does no longer have classical peptide characteristics such as enzymatically scissile peptidic 
bonds”.19 Approaches used for the development of peptidomimetics are depicted in Figure 3, 
where the starting points are either endogenous peptides or non-peptidic compounds e.g. 
natural products, or derivatives from synthetic collections.14 
 
Figure 3. Design and development of peptidomimetics.14 
There are various strategies to identify the amino acids that are essential for the activity of a 
peptide. The most common methods used include truncations, deletions, and substitutions 
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of amino acids. Then the conformational flexibility of the peptides can be reduced through 
the introduction of local or global constraints.16 The local constraints involve the 
incorporation of modified amino acids (e.g. D-amino acids, N-methyl, cyclic or β-substituted 
amino acids) or replacement of amide bonds with bioisosteres (e.g. CH=CH, CH2CH2, 
CH(OH)CH2, COCH2 or CH2NH).20, 21 IUPAC defines a bioisostere as; “A compound resulting 
from the exchange of an atom or group of atoms with another, broadly similar, atom or groups of atoms”.19 
Global constraints comprise e.g. medium- or long range cyclizations including disulfide- or 
lactam bridges. Other modifications are the development of secondary structure mimetics 
such as β-turn mimetics.17, 22, 23  
Altogether these types of modifications result in either i) a class I mimetic where the peptide 
backbone is modified using bioisosteres, ii) a class II mimetic where the entire framework is 
changed but the derivative has affinity to the same receptor as the parent peptide, or iii) a 
class III mimetic which encompasses a scaffold that places amino acid side chains crucial for 
activity in the same relative positions as in the parent peptide.15 Figure 4 shows examples of 
successfully developed type III peptidomimetics.  
 
Figure 4. Examples of type III peptidomimetics. A) A selective antagonist at the AT-2 receptor,24 
B) the HIV protease inhibitor DuP450,25 and C) the first published scaffold-based mimetic, it 
proved to act as an enkephalin mimetic.18, 26  
1.2 Targets for bioactive peptides relevant to this thesis 
1.2.1 G-protein coupled receptors 
The G-protein coupled receptors (GPCRs) are one of the most common types of receptors 
and hence attractive drug targets. A broad range of ligands such as peptide hormones (e.g. 
glucagon, insulin, oxytocin, somatostatin), or peptide neurotransmitters (e.g. somatostatin, 
enkephalin, substance P) are recognized by GPCRs. GPCR´s are characterized by an 
extracellular N-terminus, seven transmembrane helices (7TM), an intracellular C-terminus in 
association with a heterotrimeric G protein complex (containing α-, β-, and γ-subunits) 
(Figure 5).27, 28 
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Figure 5. Schematic representation of a G-protein coupled receptor embedded in a phospholipid 
bilayer. 
When the appropriate ligand binds to the receptor there is a conformational change in the 
receptor-ligand complex resulting in an activation cascade through the exchange of 
guanosine diphosphate (GDP) to guanosine triphosphate (GTP) on the α-unit in the G-
protein. The α-subunit then splits off from the β- and γ-subunits and the free α-subunit and 
the β/γ complex mediate a second messenger response via different cellular effectors e.g. 
adenylate cyclase or protein phosphatases.29-31   
1.2.1.1 Somatostatin (Somatotropin Release-Inhibiting Factor, SRIF)  
Somatostatin is an inhibitory peptide hormone isolated in 1973 from ovine hypothalamus, it 
is expressed in the central nervous system (CNS), the GI tract, and in endocrine tissues.7, 32, 
33 Somatostatin comprises 14 or 24 amino acids and exerts its action through five structurally 
related GPCR subtypes (sst1-sst5).34 The peptide functions as a neurotransmitter on e.g. the 
sst2 receptor, which is involved in the inhibition of the release of growth hormone (GH), 
glucagon and insulin.33, 34 Figure 6 shows the structure of somatostatin-14 containing the 
tetrapeptide Phe7-Trp8-Lys9-Thr10 which adopts a type II´ β-turn as the bioactive 
conformation.35, 36 Trp8 and Lys9 side chains are particularly important for the activity.37 
 
Figure 6. The primary sequence of somatostatin-14.38 
The fact that somatostatin has a short half-life in plasma (<3 min) makes the peptide 
interesting for development of stabilized mimetics. The cyclic hexapeptide L-363,301 (Figure 
7) was synthesized with a reduced ring size in comparison to somatostatin and was 
considered to be the lead compound in the development of more restricted analogs.39, 40 It is 
a highly potent agonist and inhibits the release of GH, insulin and glucagon to a greater 
extent than somatostatin. Octreotide (or Sandostatin®) (Figure 7) is a peptide-based 
somatostatin agonist used in the treatment of hormone-secreting pituitary adenomas and 
gastroenteropancreatic (GEP) tumors.41 Octreotide is stabilized by the introduction of D-
Phe1, and D-Trp4, a disulfide bridge between Cys2 and Cys7, and an amino alcohol at the C-
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terminus. The half-life of octreotide is 117 min.42 An extensive number of peptidic and non-
peptidic somatostatin agonists have received considerable attention over the years.38 The 
non-peptidic derivatives of somatostatin are mainly scaffold-based β-turn mimetics to which 
appropriate side chains are attached. The first non-peptidic analog of somatostatin was based 
on a glucose scaffold.43, 44 Other scaffolds such as benzodiazepines,45 pyrrolidine46 and 
catechol47 having the crucial side chain moieties of Trp8 and Lys9 have also been evaluated 
for their agonistic activity (Figure 7).  
 
Figure 7. L-363,301 and octreotide38 are peptidic analogs of somatostatin while the non-peptidic 
scaffold-based mimetics are represented by substituted glucose,43, 44, 48 benzodiazepine,45 and 
catechol47 derivatives.  
1.2.2 Enzymes: Silent information regulator type (Sirt) enzymes 
The function of proteins is related to post-translational modifications including acetylation, 
methylation or phosphorylation. Protein complexes such as histones undergo ε-amino 
acetylation of lysine residues.49 Histones bind DNA in the nucleosomes (Figure 8) and the 
lysine acetylation/deacetylation process affects gene regulation. The acetylation neutralizes 
the positive charge of lysine and affects the decondensation of the chromatin fibres. This 
leads then to alterations in DNA binding.49, 50 
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Figure 8. A chromosome is composed of DNA packed into chromatins. The chromatins are 
repeating units of nucleoseomes with DNA helices (red wires) wrapped around histones (blue 
filled circles) with acetyl groups on the surface (red filled circles).  
The acetylation is a reversible process involving an acetyl transfer to an ε-amino group of 
lysine catalyzed by histone acetyltransferase (HAT).51 The opposite deacetylation is catalyzed 
by histone deacetylases (HDACs). Sirtuins (Sirts or Silent Information Regulator Types) 
belong to the class III HDACs that require nicotinamide adenine dinucleotide (NAD+) as a 
co-substrate. The name sirtuin refers to the originally found Sir2 homolog in yeast.52 The 
sirtuins deacetylate not only histones but also non-histone substrates such as transcription 
factors (e.g. p53) or α-tubulin.50, 53-56 There are seven mammalian Sirt isoforms (Sirt1-Sirt7)57, 
58 localized in the nucleus (Sirt1, -6, -7), cytoplasm (Sirt2), and the mitochondria (Sirt3, -4, -
5).52, 59 Sirt1-3, -5, and 6-7 catalyze deacetylations whereas Sirt4 and -6 catalyze an adenine 
diphosphate (ADP)-ribosyl transfer reaction (the latter mechanism is not discussed in this 
thesis).  
 
In the deacetylation reaction the glycosidic bond in NAD+ is believed to break through an 
SN2-mechanism,60, 61 and a deacetylated substrate, 2´-O-acetyl-ADP-ribose, and nicotinamide 
(NAM) are formed (Figure 9).62 The acetyl group on 2´-O-acetyl-ADP-ribose equilibrates via 
an intramolecular transesterification with the 3´-O-acetylated regioisomer.63 Nicotinamide 
functions as the physiological regulator of the deacetylation process.64  
 
Nucleus
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Figure 9. The function of mammalians sirtuins is either to catalyze the deacetylation of various 
protein substrates or an ADP-ribosyl transfer reaction.65  
The sirtuins have recently become highly interesting targets for drug development as they are 
proposed to be involved in age-related diseases such as diabetes, cancer58, 66, 67 and 
neurodegenerative disorders, e.g. Parkinson’s and Alzheimer’s disease.58, 66, 68, 69 One of the 
aims of this thesis is to develop Sirt modulators. 
1.2.2.1 Deacetylation by silent information regulator type 2 (Sirt2) 
The microtubule network of a cell is composed of α-and β-tubulin proteins shaped as hollow 
cylinders in the cytosol (Figure 10).70 The microtubule is involved in the movement of 
organelles in the cell, in cell division, and cell wall formation.70, 71 Sirt2 colocalizes with the 
microtubule and hence with the α-tubulin both in vivo and in vitro.55 Sirt2 is involved in cell 
cycle regulation72 and inhibition of Sirt2 leads to hyperacetylation of α-tubulin and to 
reduced tumor growth in cancer tissues.55, 58 In addition, reports have shown that Sirt2 
inhibition leads to a decreased neuronal cell death which relates Sirt2 activity to Parkinson´s 
disease.73  
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Figure 10. The microtubule is composed of α- and β-tubulin. The polymerization and 
depolymerization processes of the subunits are highly dynamic and crucial for e.g. mitosis.70  
 
1.2.2.2 Structure of Sirt2  
The crystal structure of human Sirt2 was solved in 2001 by Finnin et al.74 The enzyme is 
composed of two domains connected by four polypeptide chains (Figure 11). The larger 
domain is a Rossmann fold domain present in many NAD(H)/(NADP(H) binding 
enzymes.75 It includes six β-strands surrounded by six α-helices and constitutes the NAD+ 
binding site. The Rossmann fold is characterized by a Gly-X-Gly sequence important for the 
NAD phosphate binding and a small pocket with charged residues to bind the ribose groups. 
Mutations in the large groove between the two domains disturb the deacetylation activity 
and this part is therefore considered as the catalytic site of the enzyme.74 The smaller domain 
has a helical module and a structural zinc binding module. The structures of the two 
domains are conserved throughout the sirtuin family.  
 
 
Figure 11. The apo structure of human Sirt2 (PDB 1J8F).74 The secondary structure is 
represented by α-helices (red), β-strands (yellow), and loops (grey/blue).  
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1.2.2.3 Inhibitors of Sirt2 
Nicotinamide is the physiological inhibitor of Sirt2 whereas sirtinol (Figure 12) was the first 
synthetic Sirt2 inhibitor explored in 2001 by Grotzinger et al.76 A number of compounds 
have been synthesized and evaluated as Sirt2 selective inhibitors such as alkylated cambinol 
derivatives,77 AGK2,73, 78 tryptamide analogs,79 and 2-anilinobenzamides.80 The binding of 
the published inhibitors have been suggested to either occur in the catalytic site or in the 
NAD+ binding site, however the binding modes of many of the developed inhibitors remain 
unknown. Substrate based inhibitors such as Nε-thioacetyl-lysine containing peptides show 
high potency but so far no selectivity is observed for Sirt2 over Sirt1.81, 82 However, a cyclic 
pentapeptide has recently been discovered as a selective Sirt2 inhibitor.60  
 
 
 
Figure 12. Structures of nicotinamide (natural regulator of Sirt2) and known Sirt2 inhibitors. 
 
1.2.2.4 The proposed role of Sirt2 in cancer   
Although Sirt2 is mainly located in the cytoplasm, the enzyme is shuttled into the nucleus 
during the mitosis.72 The Sirt2 level increases in the G2/M phase (Figure 13) and an 
overexpression of Sirt2 prolongs the mitotic phase in a normal cell cycle.72  Sirt2 is believed 
to have an effect on the check-point in the G2/M phase and ensures that the cell does not 
proceed through mitosis if exposed to any stress signal or if damaged DNA is present. 83-85 
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Figure 13. Schematic picture of the different stages in the cell cycle.86 
Wang et al. have reported that Sirt2 activity facilitates apoptosis of damaged cells, and hence 
a decreased Sirt2 concentration is important for the mitotic exit in the cell cycle.87 Certain 
cancer cell lines (e.g. HeLa cells) show a downregulation of Sirt2 which induces p53 
accumulation and eventually apoptosis of the cell.88 Sirt2 inhibitors have therefore become 
an interesting target in cancer research.85, 89 Recently, the selective Sirt2 inhibitors sirtinol90 
and AGK291 (structures shown in Figure 12) induce apoptosis of e.g. MCF-7 breast cancer 
cells and C6 glioma cells.  
1.3 Chroman-4-ones and chromones as scaffolds for bioactive compounds 
In this thesis chroman-4-ones and chromones are used as scaffolds for the development of 
bioactive compounds. These frameworks are naturally occurring derivatives containing an 
oxa-pyran ring.92, 93 Structures of chroman-4-one and chromone derivatives are illustrated in 
Figure 14. The most frequently found chromone-based natural products are the 2-aryl 
substituted chromones (flavonoids) carrying hydroxy and/or methoxy groups on the A 
and/or B rings.94, 95 They are constituents of pigments in leaves and are present in a range of 
food sources such as olive oil, tea, fruits, and red wine.96 Flavonoids are well represented in 
the literature whereas the 2-alkyl substituted chroman-4-ones and chromones are not as 
common. In addition, the literature regarding enantioselective synthesis of 2-alkyl chroman-
4-ones is limited.97, 98  
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Figure 14. The chemical structures and numbering of chroman-4-one and chromone related 
derivatives.  
The substitution pattern of the chroman-4-one and chromone scaffolds determines their 
different biological effects. Known effects of these types of compounds are antioxidant,99, 100 
antiviral,101 antibacterial activities102, or kinase inhibition.103, 104 Hence, chroman-4-ones and 
chromones can be considered privileged structures, defined as “a single molecular framework able 
to provide ligands for diverse receptors”.105-107 This thesis is mainly based on 2,6- or 2,8-
disubstituted chroman-4-ones and chromones and 2,3,6,8-tetrasubstituted chromones. 
The first clinically used chromone was khellin (Figure 15) which was extracted from the 
seeds of Ammi visnaga and isolated in its pure form in the 1930´s.94 It functioned as a relaxing 
agent in visceral smooth muscle and was later found to provide prolonged relief of bronchial 
asthma. There are currently a number of chroman/chromone based medical treatments in 
use, e.g. sodium cromoglycate (Lomudal®) which prevents the release of histamine from 
mast cells and is administrated as a disodium salt,108 and nabilone (Cesamet®) which is a 
cannabinoid used as an antiemetic drug.109 α-Tocopherol (vitamin E) occurs mainly in 
avocado, almond, and wheat germ and acts as an antioxidant and a radical scavenger.109  
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Figure 15. Khellin, sodium chromoglycate and nabilone are clinically used chromone and 
chroman derivatives. α-Tocopherol is a naturally occurring antioxidant in food. 
Substituted chroman-4-one and chromone derivatives are formed either biosynthetically110 
or synthetically. The retrosynthetic analysis for the most common pathways to derive 
chroman-4-ones and chromones is shown in Figure 16. Routes 1 and 2 require acidic or 
basic conditions in order to form the desired chromone. Route 1 involves α,β-diketones 
formed through a Baker-Venkataraman rearrangement from o-acyloxyketones.111, 112 Route 2 
involves a chalcone intermediate synthesized in a Claisen-Schmidt condensation from an 
aldehyde and an acetophenone.113, 114 As illustrated in route 3, prior an oxidation to the 
chromone the corresponding chroman-4-one derivative could be synthesized via a 
condensation reaction with an acetophenone and an aldehyde whereas route 4 involves a 
propargyl derivative formed from salicylic acid and an alkyne.115 In order to synthesize the 
desired chroman-4-one and chromone derivatives route 3 was specifically applied in this 
thesis.  
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Figure 16. Retrosynthetic analysis of common synthetic pathways to obtain chroman-4-one and 
chromone derivatives. Route 3 is applied in this thesis. 
1.4 Computational calculations as tools in medicinal chemistry 
The bioactive conformation of a peptide is of great interest in order to understand how the 
peptide binds to the target and which of the individual amino acids that are involved in the 
binding. Peptides are highly flexible in solution and adopt a large number of conformations. 
A way to determine which conformations that are prevalent in solution is to use NMR 
spectroscopy. However, as individual conformations cannot be studied using this technique, 
computational calculations using simulated solvation has become increasingly important.  
Computer based methods are of great value in medicinal chemistry in terms of calculations 
of energies and geometries of molecules.116 Two common methods available for this 
purpose are molecular mechanics (MM) and quantum mechanics (QM) calculations. 
Molecular mechanics calculations are considered to be fast, have broad applicability for a 
range of compounds, and to be sufficiently accurate. Quantum mechanics calculations are 
suitable for modeling of transitions states, and for determination of reaction paths or 
geometries. The basic idea of quantum mechanics is to determine the exact electronic 
distribution of the molecules.   
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The concept of conformational search and energy minimization using MM is based on the 
potential energy of a molecule. The potential energy is determined by factors such as bond 
stretching, angle bending, torsional angles, non-bonding interactions including van der Waals 
interactions, electrostatics and coupled energy terms. These parameters are combined to 
provide the total energy (Etot) as described in Eq. (1):   
                       Etot = Estr + Ebend + Etors + Evdw + Eelec + Ecross-term                            (1) 
Considering the first parameter in Eq. (1) the energy Estr is obtained for a bond stretch that 
deviates from an optimal geometry or unstrained value. Each deviation will increase the total 
energy. The Estr values for bonds between a large variety of atoms are empirically derived 
and are included in what is referred to as a force field.116 The same is true for other terms in 
the equation. A conformational search in MM results in low energy conformations including 
global and local minima where a conformation is mainly related to changes in torsion angles 
around single bonds. Because the bioactive conformation is not necessarily at global energy 
minima of a ligand, other low energy conformations within 12 kJ/mol from the global 
minima in solution are of interest for the search of the bioactive conformation.117  
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2. Aims of the thesis 
 
 
The general aim of this thesis was to synthesize compounds based on functionalized 
chroman-4-one and chromone scaffolds and evaluate their biological activities.   
 
The specific objectives were: 
 To develop synthetic methods to incorporate substituents in defined positions of the 
chroman-4-one and chromone frameworks (Papers I and II).  
 
 To use chroman-4-one and chromone scaffolds for the development of β-turn 
mimetics using somatostatin as a model peptide (Paper III). 
 
 To develop chroman-4-one and chromone based Sirt2 modulators (Papers IV and 
V).  
 
 To perform a structural determination study of a proline mediated cyclization 
product based on chroman-4-one (Paper VI). 
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3. Synthesis of functionalized chroman-4-one/chromone scaffolds 
 
As described in section 1.3, 2-phenyl substituted chroman-4-one/chromone derivatives are 
more prevalent in the literature than the corresponding 2-alkyl derivatives. The initial aim of 
this thesis was to develop an efficient method to synthesize 2-alkyl substituted chroman-4-
ones e.g. 2,6,8-trisubstituted chroman-4-one C (Figure 17). These derivatives were 
considered to be key intermediates for the syntheses of functionalized chroman-4-ones and 
chromones such as D and E. 
More specifically, the synthetic strategy was to react substituted acetophenones A and 
aliphatic aldehydes B to obtain the 2,6,8-trisubstituted chroman-4-ones C. A subsequent 
incorporation of a 3-substituent using appropriate methods would eventually give D or E. In 
the following section the development and optimization of various synthetic procedures to 
obtain the 2,6,8-trisubstituted chroman-4-ones C and 2,3,6,8-tetrasubstituted derivatives D 
and E will be discussed. 
 
Figure 17. The synthetic strategy to obtain functionalized chroman-4-ones/chromones C, D, and 
E. The 2-alkyl chroman-4-one derivative C is considered to be a key compound for the 
subsequent introduction of substituents. PG = protecting group. 
3.1 Introduction of substituents in the 2-position: Base mediated aldol condensation 
(Paper I) 
One common method to obtain 2-alkyl chroman-4-ones is via an enamine catalyzed reaction 
to afford 2-mono- or 2,2-disubstituted chroman-4-ones using pyrrolidine in refluxing 
toluene as reported by Kabbe et al. in 1982.118 The reactions involved o-
hydroxyacetophenones and ketones or aldehydes (aromatic or aliphatic) (Figure 18). A 
majority of the alkyl derivatives were synthesized using acetophenones without other 
substituents, it was also reported that chroman-4-ones with phenethyl as the 2-substituent 
were formed in only low yields.118 An alternative route to obtain 2-alkyl substituted 
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chroman-4-ones is to perform a Mukayiama aldol condensation which requires the use of 
TiCl4.119 Such harsh conditions are however not suitable if (acid) sensitive groups such as 
esters or nitriles are present in the acetophenone or the aldehyde.  
 
 
Figure 18. The retrosynthetic analysis of the formation of 2-alkyl substituted chroman-4-ones 
according to previously reported procedures. The reactions are mainly enamine catalyzed or 
involve the use of silyl enol ethers.118, 119 
The main aim of Paper I was to develop an efficient synthetic procedure to obtain 2-alkyl 
substituted chroman-4-ones using microwave heating. Previously, L-proline was reported to 
catalyze the formation of flavanones in DMF at 80 °C.120 The enantioselectivity obtained in 
the reaction was however low (<5%). As a starting point attempts to form the 2-alkyl 
substituted derivative 1 (Scheme 1) from 3’-bromo-5’-chloro-2’-hydroxyacetophenone and 3-
phenylpropanal. The reaction was performed in DMF using various amounts of L-proline 
(0.3 or 1.1 equiv) under microwave conditions (120 or 170 C) or classical heating (80 °C). 
Also different reaction times (1, 21 or 48 h) were examined. Independent on the choice of 
conditions the reaction resulted in low yields (8-38%) of product.  
 
 
Scheme 1. The synthesis of derivative 1 was used as a model reaction for the optimization of the 
procedure to obtain 2-alkyl substituted chroman-4-ones.  
Instead other bases (pyrrolidine, diisopropylamine (DIPA), morpholine, piperazine, and 
piperidine), temperatures (100 °C or 170 °C), and solvents (EtOH, water, or toluene) were 
evaluated under microwave conditions for 1 hour (Table 1). The desired chroman-4-one 1 
was obtained as a racemic mixture in low to moderate yields using pyrrolidine as the base 
(15-52%) (Table 1, entry 1). The yields of the reaction were improved (61-88%) using DIPA 
or morpholine in EtOH or toluene (Table 1, entries 2 and 3). Piperazine and piperidine 
(Table 1, entries 4-5) gave 1 in moderate to good yields in EtOH at 170 ºC (61 and 63%, 
respectively).  
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Table 1. The screening of conditions for the formation of derivative 1.a 
  EtOH Water Toluene 
Entry Baseb 100 °C 170 °C 100 °C 170 °C 100 °C 170 °C 
1 Pyrrolidine 52 16 36 15 30f n.r.g 
2 DIPA 71 88c 45 48 n.r.g 78 
3 Morpholine 68 72 12 72 n.r.g 61 
4 Piperazine  61d     
5 Piperidine  63e     
6 DIPEA  81     
aIsolated yields. b1.1 equiv of the base was used. c0.3 equiv of DIPA resulted in lower yield and formation of 
aldehyde condensation products. dUnreacted 3-bromo-5-chloro-2-hydroxyacetophenone was recovered. e0.3 
equiv of piperidine resulted in lower yield and formation of aldehyde condensation products. fThe yield was 
estimated from 1H NMR spectra on the crude reaction mixture due to purification problems. gno reaction. 
In summary, the reaction gave the highest yield, 88% of 1 (Table 1, entry 2) when using 
DIPA in EtOH with microwave heating at 170 ºC for 1 h. A control experiment with the 
tertiary amine diisopropylethylamine (DIPEA) also gave high yields (81%) of 1, which 
implies that the reaction proceeds via an aldol condensation rather than an enamine 
mechanism. The proposed mechanism for the base mediated aldol condensation of the 
formation of the chroman-4-ones is shown in Scheme 2.  
 
 
Scheme 2. The proposed mechanism for the base mediated formation of 2-alkyl substituted 
chroman-4-ones. The reaction involves an aldol condensation and a subsequent oxa-Michael 
addition.  
The scope of the reaction was further investigated by screening different acetophenones and 
aldehydes as illustrated in Table 2. 
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Table 2. Screening of different acetophenones and aldehydes to obtain 2-alkyl substituted 
chroman-4-ones 1-16.a  
 
Entry R2 Product Yield (%)b
1 CH2CH2Ph 1 88
2 CH2CH2(1-naphthyl) 2 84
3 CH2CH2(3-indolyl) 3 86
4 CH2CH2(N-Bn)-3-indolyl 4 84
5 CH2CH2(N-Ts)-3-indolyl 5 74 
6 (CH2)4CH3 6 80
7 CH(CH3)2 7 43
8 cyclohexyl 8 46
9 Ph 9 24
10 4-OMePh 10 n.r.c,e 
11 4-CF3Ph 11 n.r.e 
12 CH2CH2Ph 12 70d
13 CH2CH2Ph 13 38d
14 CH2CH2Ph 14 17d 
15 (CH2)4CH3 15 26 
16 (CH2)4CH3 16 37 
aReagents and conditions: a) DIPA, 170 °C, 1 h, EtOH, MW. bIsolated yields. c32% of the chalcone was 
isolated. dEstimated yield of product according to 1H NMR spectra on the crude reaction mixture, the 
product could not be isolated due to purification problems. eno reaction 
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In general the reaction resulted in good to high yields using aliphatic aldehydes (entries 1-6). 
However branched aldehydes bearing isopropyl or cyclohexyl groups (entries 7-8) gave 
somewhat lower yields (43 and 46%, respectively). This is probably due to sterical hindrance 
in the aldol reaction. Also aryl aldehydes were evaluated (entries 9-11)                       
but resulted in low yields when using benzaldehyde (entry 9) and gave no or only traces of 
product with 4´-substituted benzaldehydes (entries 10-11), instead chalcone intermediates 
were isolated.  
 
To investigate whether the method is general regarding the substitution in the acetophenone 
also 4´-fluoro-, 5´-nitro-, 5´-methyl-, and 5´-methoxyacetophenone were used as starting 
materials (entries 12-15). The desired products were formed in low to good yields (17-70%) 
as estimated from 1H NMR spectra of the crude reaction mixtures. In addition, the 2-
hydroxyacetophenone without any other substituents gave chroman-4-one 16 in 37% yield 
(entry 16). Thus, the developed method seems to be general for aliphatic aldehydes but 
results in lower yields when bulky or aromatic aldehydes are used. Higher yields of the 
chroman-4-ones are obtained when electron withdrawing groups on the acetophenone are 
present.  
3.2 Introduction of substituents in the 3-position (Papers I and II)  
The synthetic strategy for further functionalization of the chroman-4-one scaffold was 
planned to go via 3-bromo substituted 2-alkyl chroman-4-ones (Figure 19). The bromine 
could then serve as a handle in e.g. substitution and elimination reactions. In addition, 
halogens such as Cl and Br in the 6- and 8-positions, respectively, were considered as 
handles for further Pd mediated reactions.   
 
Figure 19. The strategy to synthesize 2-alkyl-3-bromochroman-4-ones in order to functionalize 
the 3-position and form substituted chroman-4-one and/or chromone derivatives.  
3.2.1 Formation of 3-amino-, 3-bromo, and 3-acetoxychromones 
The synthesis towards further functionalized chroman-4-ones was performed via the 
formation of 3-bromo derivatives 1a-2a, 6a, 8a-9a, and 15a-19a (Scheme 3) starting from 
chroman-4-ones 1-2, 6, 8-9, and 15-19. The chroman-4-ones 17-19 were commercially 
available. 
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Scheme 3. The formation of 3-bromo chroman-4-one derivatives. Reagents and conditions: (a) 
CuBr2, CHCl3/EtOAc, reflux, 2-6 h (compounds 1a-2a, 6a, 8a-9a, 15a-16a) or Py·Br3, CH2Cl2, rt, 
30 min (compounds 17a-19a).  
Interestingly, the formation of 3-brominated derivatives gave cis-isomers as the major 
products as shown in Table 3. For instance, derivative 1a (entry 1) resulted in a 
diastereomeric ratio of 80:20 according to 1H NMR spectroscopy. 
Table 3. The cis:trans ratio obtained in the 3-bromination reaction to obtain the chroman-4-ones 
1a-2a, 6a, 8a-9a, and 15-16a.a 
Entry cis:trans ratio Product
1 80:20 1a 
2 70:30 2a 
3 75:25 6a 
4 99:1 8a 
5 75:25 9a 
6 75:25 15a 
7 78:22 16a 
aThe cis:trans ratio observed according to 1H NMR spectroscopy after purification.  
The results obtained for derivative 1a were confirmed using computational calculations. 
Figure 20 shows a simplified structure of the 3-brominated chroman-4-one. After a 
molecular mechanics based conformational search (MacroModel v. 8.0, MM3* force field),121 
one low energy conformation of each isomer was reevaluated using density functional theory 
(DFT) (B3LYP/LACVP*).122 The results were in full agreement with the 1H NMR spectral 
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interpretation and showed that the cis-isomer was thermodynamically more stable than the 
trans-isomer.  
                                         
Figure 20. The cis-isomer is the dominating product in the bromination reaction using CuBr2. 
The conformation having bromine in an axial position and the phenethyl substituent in the 
equatorial position was favored.   
The 3-brominated products 1a-2a, and 6a were used in further functionalizations of the 
scaffold. Attempts to introduce an amino group in the 3-position to form 20 via the 
diastereomeric mixture of 1a were first performed (Scheme 4). Using NaN3 in DMF the 
desired amine 20 was obtained in 39% yield accompanied with the chromone derivative 23 
(49% yield). 
 
 
Scheme 4. Formation of chromones. Reagents and conditions: (a) NaN3, DMSO, rt, 3 h; (b) 
CaCO3, DMF, 100 C, 10 min; (c) Acetic anhydride, pyridine, rt, o.n. 
Attempts were performed to improve the yields of 20 by e.g. increasing the amount of trans-
isomer of 1a using other bromination methods (Br2 in AcOH or pyridinium tribromide 
(Py·Br3) in AcOH or THF). By changing solvent, Py·Br3 in dichloromethane at room 
temperature gave 1a in 92% yield with a cis:trans ratio of 40:60 according to 1H NMR spectra. 
The result may be explained by pyridine preventing enolization of the trans-isomer and 
thereby avoiding the epimerization to the cis-isomer. However, an epimerization occurred 
instead during the purification by column chromatography on silica resulting in a cis:trans 
ratio of 60:40. Interestingly, when repeating the NaN3 experiment in DMF using the cis:trans 
(40:60) mixture it was shown that the diastereomeric ratio of 1a did not affect the ratio of 
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compounds 20 and 23, chromone 23 was still the major product. The azide reaction was 
therefore evaluated further in attempts to favor the formation of 20 over 23. In this effort, 
different azide sources (NaN3, TMSN3 or TMGN3), solvents (DMF, DMSO, THF, acetone 
or MeCN) and temperatures were tested. Unfortunately, this did not substantially improve 
the yield of 20, the best result was obtained by using 10 equiv of NaN3 in DMSO which 
provided 20 in 42% and 23 in 43% yields. A subsequent acetylation of 20 gave the 22 in 87% 
yield. The azide method was also applied to the naphthyl derivative 2a and resulted in 32% 
of the amine 21 and 51% yield of the chromone 24. The outcome of the amination reaction 
was probably due to an epimerization of the trans- to the cis-isomer when using NaN3, which 
then promotes an E2-reaction. Alternatively, an azide ion attacks the trans-isomer forming 
the cis-2-alkyl-3-azido derivative which then eliminates HN3 to form the corresponding 
chromone.  
 
Also the 3-substituted chromone 27 was synthesized (Scheme 5). A dibromination of 1 with 
Py·Br3 at 80 C using microwave heating gave a smooth conversion to the dibrominated 
intermediate 26. An HBr-elimination of crude 26 yielded the brominated chromone 27 in 
77% (over two steps) using CaCO3 in DMF.  
 
 
 
Scheme 5. Formation of chromones 27 and 28. Reagents and conditions: (a) i) Py·Br3, CH2Cl2, 
80 C, 70 min, MW; b) CaCO3, DMF, 100 C, 10 min, MW; (c) i) Isoamyl nitrite, HCl, THF, 60 
C, 7 h, MW, ii) AcCl, TEA, CH2Cl2, 2 h, rt.  
Other bases such as DBU or TEA in dichloromethane or Cs2CO3 in DMF also gave 27 but 
were always accompanied with other impurities. CaCO3 in DMF was then used to prepare 
chromone 23-25 in 71-94% yields from the mono-brominated compounds 1a-2a, and 6a 
(Scheme 4). Finally, the 3-hydroxychromone analog was synthesized from 1 using isoamyl 
nitrite and HCl in EtOH.123 The reaction was performed at different temperatures (60, 70, 
100, and 120 C) using microwave as well as conventional heating sources and by using 
different solvents (EtOH, iPrOH or THF). For most of the experiments, the desired alcohol 
was obtained in significant amounts however always accompanied with several by-products, 
which complicated the purification. The best result was obtained at 60 °C in EtOH using 
conventional heating. To facilitate the purification, the alcohol was acetylated using acetyl 
chloride and triethylamine, which gave the 3-acetoxy chromone 28 in 49% yield over two 
steps.  
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3.2.2 Introduction of a 3-aminomethyl group in chroman-4-ones 
The introduction of an aminomethyl group in the 3-position of chroman-4-ones can be 
achieved using various methods, e.g. via a combined Mannich/Michael reaction or a metal 
mediated Reformatsky type reaction. Both approaches have been tested and the results will 
be discussed below. Further studies on the use of the Mannich reaction will be discussed in 
Chapter 7. 
3.2.2.1 The Mannich/Michael addition approach 
Wallén et al. earlier reported the introduction of a Cbz-protected 3-aminomethyl group via a 
3-methylenechroman-4-one intermediate using an efficient microwave assisted Mannich 
reaction followed by an aza-Michael addition.113 We applied this method on derivatives 1 and 
4 (Scheme 6). The initial Mannich reaction was run at 165 C for 10 min in a microwave 
cavity and resulted in the formation of the 3-methylene substituted products 29 and 30, 
respectively, together with approximately 40% of the starting materials according to 1H 
NMR spectroscopy of the crude reaction mixtures.  
 
Scheme 6. Reagents and conditions: (a) Me2NH×HCl, (CH2O)n, dioxane, 165 C, 10 min, MW; 
(b) CbzNH2, Tf2NH, MeCN, rt, o.n. 
Similar results were obtained after variation of the amounts of amine and aldehyde (0.3, 2, 
and 4 equiv), amine sources (Me2NH×HCl, morpholine, piperidine) and solvents (MeCN, 
CH2Cl2, dioxane, THF, EtOH). Instead of attempting to isolate the methylene derivatives 29 
and 30, the crude product mixtures were used directly to obtain the protected primary amine 
in the 3-position. The aza-Michael addition using Cbz-NH2 in MeCN at room temperature 
overnight gave however only low yields (<30%) of the desired products. Neither variation of 
the amounts of CbzNH2, addition of other amine nucleophiles (Me3SiN3 or NaN3), choice 
of solvents (MeCN, AcOH/H2O, CH2Cl2), addition of Lewis acids (Tf2NH, ZrOCl2×H2O 
or NAFION SAC-13) nor different temperatures (60 C, rt, -20 C) did improve the yield of 
the amine-containing derivatives 29a or 30a.  
Instead the focus was directed to the 3-bromo derivatives for the introduction of the 
aminomethyl group in the 3-position. The idea was to use the 3-brominated chroman-4-ones 
in a Reformatsky type reaction with SmI2 and a suitable cyano-containing electrophile 
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(Figure 21).124 Eventually the nitrile was to be reduced to the corresponding aminomethyl 
group.  
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Figure 21. The synthetic strategy to introduce an aminomethyl group as the substituent in the 3-
position of chroman-4-one using a SmI2 mediated Reformatsky reaction. PG=protecting group 
3.3.2.2 Sm(II) medited α-cyanation of 3-bromo-chroman-4-ones (Paper II) 
Samarium (Sm) belongs to the lanthanides. The metal possesses a high oxidation potential         
(-1.41 V and -1.55 V in THF and water, respectively) and salt equivalents of Sm are common 
reagents in single electron transfer (SET) reactions.125-128 Samarium diiodide (SmI2) has 
become a useful samarium reagent in coupling reactions of alkyl halides and ketones (Barbier 
reactions)129 and aromatic carbonyls (pinacol reactions),130 reductions of ketones,131 and nitro 
groups,132 deoxygenations,133 and in Reformatsky type reactions.128, 134 The mechanism of 
SmI2 promoted reactions with alkyl halides or carbonyl compounds is proposed to proceed 
in a two-step process (Scheme 7).128  
 
Scheme 7. a) A reaction between SmI2 and an alkyl halide occurs via stepwise one-electron 
transfer reactions and b) SmI2 mediated activation of carbonyl compounds. 
The reactivity of SmI2 varies depending on choice of solvents (THF, tetrahydropyran (THP), 
acetonitrile, water, benzene), co-solvents (hexamethylphosphoramide (HMPA), N,N’-
dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP)), proton-donors (amines, 
alcohols, water, glycol), or addition of metal salts (e.g. LiCl, NiI2).127, 135 For the initial 
screening of the desired conditions, 3-bromo-chroman-4-one 17a was used as the model 
compound. Tosyl cyanide (TsCN)136 was selected as the electrophile and THF as the solvent. 
The experiments were run at room temperature or -78 C and SmI2 was used with or 
without the additives tetramethylguanidine (TMG), trimorpholinophosphortriamide 
(TMPA), or tripyrrolidinophosphortriamide (TPPA) (Figure 22). According to GC/MS 
analysis the reactions resulted in a mixture of the desired product 17b accompanied by the 
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dehalogenated product 17. Using bromide (SmBr2) or hexamethyl disilazane (Sm(HMDS)2) 
as the counter ions resulted mainly in the dehalogenated product 17.  
 
Figure 22. Structure of the additives TMG, TMPA, TPPA, and KHMDS used in the 
optimization of the SmI2 mediated Reformatsky reaction.  
Interestingly, when SmI(HMDS) was used instead, 3-cyanochroman-4-one 17b was obtained 
in 99% yield (Scheme 8). The results indicate that the ligands on the samarium had a great 
impact on the competing dehalogenation reaction.  
 
Scheme 8. The optimization procedure for the formation of the 3-cyanochroman-4-one 17b. 
The counter ions had a crucial impact on the outcome on the 3-cyanation reaction. The highest 
selectivity was obtained using 1:1 equiv of SmI2 and KHMDS, respectively. The yields were 
determined by GC/MS analysis after work up using dodecane as internal standard.  
To expand the scope of the reaction a number of electrophiles such as benzoyl chloride, 
acetyl chloride, benzyl bromide, cyanic bromide, 1-chlorobutane, ethynyl p-tolyl sulfone, 
benzyl isocyanate, and benzaldehyde were evaluated. Unfortunately only the corresponding 
dehalogenated product, traces of products and/or recovered starting material could be 
detected. Also a selection of structurally diverse 3-bromochroman-4-ones was synthesized as 
substrates for the reaction. For example, it was desired to incorporate a hydrolysis labile 
group such as an ester to evaluate the scope of the method. It was therefore decided to 
synthesize the 3-bromo-chroman-4-one derivative 34a. The product was synthesized in a 
five-step procedure including an acetylation, a Fries-rearrangement, and a bromination in the 
aromatic ring to form 33 (Scheme 9). After the cyclization to the chroman-4-one 34 the 3-
bromination resulted in a cis:trans ratio of 77:23 of 34a which is in agreement with previous 
bromination experiments (section 3.2.1).  
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Scheme 9. Formation of 2,3,6,8-tetrasubstituted derivative 34a used as starting material in the 
SmI2 mediated Reformatsky reaction. Reagents and conditions: (a) AcCl, TEA, CH2Cl2, rt, o.n.; 
(b) AlCl3, DCE, 30 min, 170 C, MW; (c) NBS, DMF, 0 °C→rt, 12 h; (d) Hexanal, DIPA, EtOH, 
1 h, 170 ºC, MW; (e) CuBr2, EtOAc/CH2Cl2, reflux, 2 h.  
Moreover 2-aryl substituted derivatives were of great interest in the evaluation of the 
method. The flavanone 9a and the 3-bromo substituted flavanone 35a113, 137 were included in 
the study.  
 
Scheme 10. The flavones 9a and 35a used in the SmI2 mediated Reformatsky reaction.  
Using various 3-brominated derivatives the corresponding 3-cyanochroman-4-ones could be 
synthesized followed by an oxidation with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
(DDQ) to the 3-cyanochromones (Table 4). Interestingly, in contrast to the corresponding 
brominated products where the cis-isomer was favored, the trans-isomers of 3-
cyanochroman-4-ones 1b, 8b-9b, 15b-19b, and 34b-35b were the major isomers. The result 
is most likely due to sterical hindrance from the nitrile functionality that favor the trans-
isomer over the cis-isomer. The mechanism for the initial 3-cyanation reaction is believed to 
proceed via a carbonyl activation as described in Scheme 7. 
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Table 4. The formation of 3-cyano substituted chromone derivatives.a 
 
 
Substrate 
 
 
R2 
 
 
R6 
 
 
R8 
 
cis:trans 
3-bromo 
 
cis:trans  
3-cyanob 
 
 
Product 
 
Yield 
(%)c 
 
17a H H H n/a n/a 17c 49 
18a H Cl H n/a n/a 18c 77 
19a H Me H n/a n/a 19c 62 
15a (CH2)4CH3 OMe H 75:25 45:55 15c 42 
16a (CH2)4CH3 H H 78:22 18:82 16c 75 
8a C6H11 Cl Br 99:1 25:75 8c 76 
1a CH2CH2Ph Cl Br 80:20 45:55 1c 59 
34a (CH2)4CH3 CH2COOMe Br 77:23 32:68 34c 61 
35a Ph H H 65:35 25:75 35c 65 
9a Ph Cl Br 75:25 40:60 9c 61 
aReagents and conditions: (a) i) SmI2, KHMDS, TsCN, THF, -78 C, 2 h; (b) DDQ, dioxane, rt, 2 h. bThe 
cis:trans ratio was obtained from 1H NMR spectra.  cIsolated yields over two steps.  
3.3.2.3 Reduction of 3-cyanochromone to afford 3-aminomethylchroman-4-one  
The 3-cyanochromone 1c was used as a model compound in the investigations of the 
reduction of the nitrile to the corresponding primary amine. Attempts using 
NaBH4/CoCl2×6H2O138 or BH3·SMe2139 resulted in traces of enaminone 36 (Scheme 11) 
together with a mixture of unidentified products, whereas DIBAL-H140 in THF at -78 C 
gave 36 in 66% yield. Attempts to reduce the nitrile moiety in 1c with LiAlH4 at -78 C only 
gave a selective reduction of the double bond to the saturated 3-cyanochroman-4-one 1b. An 
attempt to hydrolyze the nitrile function in 1c using conc. H2SO4 at 90 C gave the 
corresponding amide together with a sulfonation in the para-position on the phenyl ring in 
the 2-position.  
 
Scheme 11. Formation of enaminone 36. Reagents and conditions: (a) DIBAL-H, CH2Cl2, -78 
C, 3 h.  
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3-Cyanochromone 17c without any substituents in the 2-, 6- or 8-positions gave a mixture of 
unidentified products using DIBAL-H or LiAlH4. Instead the 2-alkyl-3-cyanochroman-4-one 
16b was used as a model compound (Scheme 12). Catalytic hydrogenation of 16b using an 
H-cube® apparatus charged with column-based Pd/C (10%) with EtOH as solvent, resulted 
in a selective reduction of the carbonyl group to the alcohol. A subsequent reduction of the 
nitrile group of the crude product with Ra/Ni in MeOH/THF followed by a Boc-protection 
of the primary amine afforded a diastereomeric mixture of 37 in 41% yield over three steps. 
Eventually an oxidation of the alcohol to the ketone using TPAP/NMO was made. This 
gave the desired 3-aminomethylated derivative 38 in 68% yield and a cis:trans ratio of 75:25 
according to 1H NMR spectroscopy. 
 
Scheme 12. Synthesis of compound 38. Reagents and conditions: (a) i) H2, 10% Pd/C, EtOH, rt, 
ii) H2, Ra/Ni, MeOH/THF, rt, iii) Boc2O, TEA, THF, rt, o.n.; (b) TPAP, NMO, CH2Cl2, MeCN, 
rt, 6 h. 
3.4 Introduction of substituent in the 6-position of the chroman-4-one 
So far, the chroman-4-one and/or chromone scaffolds have been functionalized with alkyl 
groups in the 2-position, an amine, a bromine, an acetoxy, and an aminomethyl group in the 
3-position. We were also interested in the functionalization of the 6-position of the 
chroman-4-one.  
3.4.1 Synthesis of chroman-4-one derivative useful as a building block in the 
synthesis of peptide analogs  
In addition to derivative 34a which possesses a methyl acetate moiety in the 6-position a 
tyrosine based model analog (43) was also synthesized (Scheme 13). The 2-phenethyl 
substituted chroman-4-one 43 was synthesized from L-tyrosine141, 142 in an efficient five-step 
sequence involving acetylation/Fries rearrangement, esterification, amine protection, 
bromination and eventually an aldol condensation/cyclization. The chroman-4-one 43 was 
obtained as diastereomeric mixture in an overall yield of 44%. This amino acid derivative can 
be used for incorporation into a peptide sequence as such or can after appropriate 
substitutions e.g. act as a fluorescent label in peptides.143  
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Scheme 13. Synthesis of a tyrosine based chroman-4-one. Reagents and conditions: (a) AcCl, 
AlCl3, 4-nitrobenzene, 100 °C, 7 h; b) SOCl2, MeOH, -8 °C→rt; c) Benzyl chloroformate, 
Na2CO3, EtO2/H2O, rt, o.n.; d) NBS, MeCN, 0 °C→rt, o.n.; e) 3-Phenylpropanal, MeOH, 1 h, 
170 °C, MW.  
3.5 Introduction of substituents in 8-position of chroman-4-ones and chromones  
In one subproject the incorporation of an alkyl group in the 8-position of the chroman-4-
one and chromone scaffolds was considered to be of great interest. One strategy was to 
incorporate substituents in the 8-position using the Br-substituent in a Sonogashira 
reaction.144, 145 A Sonogashira reaction is a coupling between aryl or alkenyl halides or 
triflates and terminal alkynes as illustrated in Figure 23.  
 
Figure 23. Schematic overview of a Sonogashira reaction. The substrates comprise an aryl or 
vinyl halide or triflate and a terminal alkyne.  
To introduce a Boc-protected propargylamine moiety in the 8-position the reaction was 
performed using N-Boc-progargylamine in the presence of CuI, PdCl2(PPh3)2, TEA, and the 
chroman-4-ones 1-5 or chromones 20-24, and 34c in THF. The mixture was heated in a 
microwave cavity for 30 min at 120 ºC to obtain the desired products 44-51 in moderate to 
good yields (41-69%) (Table 5). Disappointingly, using chroman-4-ones 3-5 did not result in 
any product formation. A subsequent reduction using catalytic hydrogenation of the alkyne 
moiety to the alkane in the 8-position resulted in products 44a-50a, respectively, in moderate 
to high yields (41-80%). The tetrasubstituted derivative 51 resulted in a reduction of the 
alkyne to the alkane and a reduction of the carbonyl to the corresponding alcohol in one step 
(for structures see Scheme 15).  
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Table 5. Formation of derivatives 44a-50a after a Sonogashira reaction and a subsequent 
catalytic hydrogenation.a 
 
Substrate R2 R3 R6 
Product 
alkyne 
Yield 
(%)b 
Product 
alkane 
Yield 
(%)b 
1 
2 
CH2CH2Ph 
CH2CH2(1-naphthyl) 
H,H 
H,H 
Cl 
Cl 
44 
45 
50 
62 
44a 
45a 
80 
56 
3 CH2CH2(3-indolyl) H,H Cl  n.r.c   
4 CH2CH2(N-Bn)-3-indolyl H,H Cl  n.r.c   
5 CH2CH2(N-Ts)-3-indolyl H,H Cl  n.r.c   
20 CH2CH2Ph NH2 Cl 46 59 46a 54 
22 
23 
21 
24 
CH2CH2Ph 
CH2CH2Ph 
CH2CH2(1-naphthyl) 
CH2CH2(1-naphthyl) 
NHAc 
H 
NH2 
H 
Cl 
Cl 
Cl 
Cl 
47 
48 
49 
50 
63 
69 
41 
61 
47a 
48a 
49a 
50a 
60d 
80 
41 
71 
34c (CH2)5CH3 CN CH2COOMe 51 48 51a 75e 
aReagents and conditions: (a) N-Boc-progargylamine (4.0 equiv), CuI (0.1 equiv), PdCl2(PPh3)2 (0.1 equiv), 
TEA (10 equiv), THF, 30 min, 120 ºC, MW; (b) H2, 10% Pd/C, MeOH, rt, 2-4 h. bIsolated yields. cNo 
reaction. dYields obtained from 1H NMR spectra on the crude reaction mixture. eThe carbonyl was also 
reduced under the catalytic hydrogenation. Yield was obtained from 1H NMR spectra on the crude reaction 
mixture (the structure of 51a is shown in Scheme 15).  
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4. Substituted chroman-4-ones and chromones as β-turn 
peptidomimetics  
 
The 2,3,6,8-tetrasubstituted chromone system can adopt a conformation that is similar to 
that of a β-turn of a peptide (Figure 24). By using somatostatin as a model peptide the 
objective of this study was to develop β-turn mimetics using chroman-4-ones and 
chromones substituted with amino acid side chain equivalents.  
O
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Figure 24. A 2,3,6,8-tetrasubstituted chromone scaffold as a potential β-turn mimetic. 
4.1 Design of substituted chroman-4-one and chromone derivatives as 
peptidomimetics of somatostatin (Paper III) 
The β-turn of somatostatin is composed of the amino acids Phe7, Trp8, Lys9, and Thr10 
(Figure 25). By using somatostatin as the model peptide the idea was to introduce 
substituents in the 2- and 8-positions on the chroman-4-one/chromone resembling the 
crucial tryptophan and lysine side chains. Glycine moieties representing N- and C-terminals 
(Figure 25) were positioned as 3- and 6-substituents. They could for example be used as 
handles for incorporation of the substituted scaffold into a peptide chain. 
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Figure 25. The β-turn in somatostatin is composed of Phe7, Trp8, Lys9, and Thr10. Phe7 and 
Thr10 are replaced by glycine residues representing N- and C-terminals in the 3- and 6-positions 
of the chromone scaffold. The side chains of Trp8 and Lys9 residues are somewhat modified 
when introduced in the 2- and 8-positions, respectively, of the chromone scaffold.  
In order to confirm the assumptions that substituted chroman-4-ones and chromones could 
mimic a β-turn of somatostatin computational studies were performed. Five different β-turn 
structures (I, I´, II, II´ and VIII)10 comprising the Phe7-Trp8-Lys9-Thr10 sequence of 
somatostatin were selected for modeling studies in order to investigate if any of these were 
similar to the chroman-4-one and chromone scaffolds.  
For structure simplification the Trp8 and Lys9 side chains in the i+1 and i+2 positions in all 
turns were replaced by methyl groups (Figure 26a) for structural simplification. Further, 
Phe7 and Thr10 in the i+2 and i+3 positions were replaced by glycine residues to give the 
sequence Ac-Gly-Ala-Ala-Gly-NHMe. The chroman-4-one and chromone scaffolds were 
simplified in the same way having methyl groups in the 2- and 8-positions, an acetylated N-
terminus in the 3-position and a methylamidated C-terminus in the 6-position (Figure 26b). 
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Figure 26. a) The simplified β-turn used in the computational calculations; b) Substituted and 
simplified chroman-4-one and chromone derivatives used in the initial molecular mechanics 
calculations; b) Chroman-4-one and chromone derivatives substituted with Lys and Trp side 
chains in the 2- and 8-positions, respectively, used in the final molecular mechanics calculations.  
Molecular mechanics calculations were used for energy minimization of the selected β-turn 
structures using the OPLS2005 force field as implemented in the MacroModel program 
v.9.7.121 Conformational constraints were introduced to keep the desired peptide turn 
structure during the energy minimization procedure. The energy minimized conformations 
were manually superimposed with different low energy conformations identified in 
conformational analyses of the 2,3,6,8-tetrasubstituted chromone and the four different 
stereoisomers of the chroman-4-one scaffolds, respectively. Of the energy minimized 
tetrapeptide structures the type II and II´ β-turns gave good alignments with the global 
minimum conformations of the chroman-4-one and the chromone scaffolds (results not 
shown).  
In order to investigate the preferred conformations of the crucial Trp8 and Lys9 amino acid 
side chains in the i+1 and i+2 positions of the tetrapeptide, conformational analyses were 
performed on the type II and II´ β-turns. Further, conformational analyses were also 
performed on the different stereoisomers of the 2,3,6,8-tetrasubstituted chroman-4-one 
scaffold with methyl groups in the 3- and 6-positions, a 2-(3-indolyl)ethyl group in the 2-
position and a 3-aminopropyl moiety in the 8-position (Figure 26c).  
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                                                         (a)                       (b) 
Figure 27. (a) Alignment of one conformation (ΔE= 12.2 kJ/mol) of the 2R,3S stereoisomer of 
the 2,3,6,8-tetrasubstituted chroman-4-one (green) with a low energy conformation (ΔE= 5.1 
kJ/mol) of the type II β-turn (yellow); (b) Alignment of a low energy conformation (ΔE = 6.2 
kJ/mol) of a 2,3,6,8-tetrasubstituted chromone derivative (green) and the global minimum 
conformation of the type II´ β-turn (yellow). 
Conformations with relative energies above 21 kJ/mol were discarded. Interestingly, all 
conformations of the 2S,3S- and 2R,3R disubstituted chroman-4-ones that had ΔE < 7.8 
kJ/mol preferentially adopted a diaxial relationship between the 2- and 3-substituents. A 
conformational analysis with dihedral constraints was performed on the type II and type II´ 
β-turns of Ac-Gly-Trp-Lys-Gly-NHMet. Different low energy conformations of these β-
turns and the four different stereoisomers of the chroman-4-one scaffold were manually 
superimposed and gave good alignments with no significant difference between the 
stereoisomers. Figure 27a shows a selected alignment of a low energy conformation of the 
2R,3S-isomer of the chroman-4-one and a low energy conformation of the type II β-turn. 
The alignment of the global minimum conformation of the II´ β-turn and a low energy 
conformation of the more rigid 2,8-disubstituted chromone ring (ΔE = 6.2 kJ/mol) is shown 
in Figure 27b.  
Thus, molecular mechanic calculations on the chroman-4-one and chromone scaffolds show 
that they mimic type II and type II´ β-turn structures, respectively. The same types of β-
turns have been identified in previous studies of other bicyclic systems used as potential β-
turn mimetics of somatostatin.23 These results prompted us to synthesize chroman-4-one 
and chromone derivatives and test them for affinity at the somatostatin receptors sst2 and 
sst4. Studies of the binding mode and the --interactions between somatostatin and its 
receptor using molecular modeling have shown that it is feasible to replace the indole moiety 
in Trp8 with either a phenyl or a naphthyl group without any decrease in activity.146 To 
simplify the synthesis the 2-(3-indolyl)ethyl moiety was therefore replaced by phenethyl or 2-
(1-naphthyl)ethyl groups in the 2-position of the chroman-4-one and the chromone 
scaffolds. 
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4.2 Synthesis of substituted chroman-4-ones 52-55  
The chroman-4-ones 44a-45a and chromones 48a and 50a previously synthesized (Table 5) 
were selected for testing as potential β-turn mimetics of somatostatin. A Boc-deprotection 
using HCl in MeOH afforded the unprotected alkylamine derivatives 52-55 (Scheme 14). 
The biological evaluation is described in section 4.3. 
 
Scheme 14. Synthesis of the potential somatostatin β-turn mimetics 52-55. Reagents and 
conditions: (a) 3M HCl in MeOH, rt, o.n. 
4.2.1 Synthesis of building block 57 
In order for the developed β-turn mimetic scaffold to be useful as a building block in 
peptide synthesis, the 2,3,6,8-tetrasubstituted chroman-4-one 57 was synthesized as a model 
compound (Scheme 15). A catalytic hydrogenation (Pd/C) of 51 led to a reduction of both 
the alkyne moiety and the carbonyl group (51a). The crude mixture was directly used in the 
next step when the nitrile functionality in the 3-position was reduced with Ra/Ni under a H2 
atmosphere to give 56. Due to solubility problems the primary amine was Fmoc-protected 
prior the oxidation of the secondary alcohol to afford 57 as a mixture of diastereomers. The 
derivative contains a Fmoc-protected aminomethyl group in the 3-position and a methyl 
acetyl moiety in the 6-position that could be used as handles in the synthesis of modified 
peptides. The derivative corresponding to a building block useful for the synthesis of 
somatostatin based pseudopeptides has not yet been synthesized. 
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Scheme 15. Formation of tetrasubstituted chroman-4-one 57. Reagents and conditions: (a) H2, 
10% Pd/C, EtOH, rt; (b) H2, Ra/Ni, MeOH/THF, rt; (c) i) Fmoc-ONSu, NaHCO3, 
dioxane/water, rt, o.n., ii) TPAP, NMO, CH2Cl2, MeCN, rt, 6 h. 
4.3 Biological evaluation of compounds 53 and 55 as mimetics of somatostatin 
Derivatives 53 and 55 were selected and sent to Euroscreen147 for testing of their affinities 
for human sst2 and sst4 receptors using a radioligand binding assay with sst28 (a natural 
agonist) as a reference.148 Interestingly, 53 and 55 showed similar affinities for the two 
receptors (Table 6). The activity of the derivatives was also comparable to that of other non-
peptidic somatostatin β-turn mimetics (Figure 7). 
Table 6. Affinities of 53 and 55 at the human sst2 and sst4 receptors.a 
ligand Ki, sst2 Ki, sst4 
sst28 0.030 nM 1.34 nM 
53 6.85 µM 7.09 µM 
55 2.66 µM 1.17 µM 
a125I-Tyr11-SRIF was used as the radiolabeled ligand. 
38 
 
5. Substituted chroman-4-ones and chromones as Sirt2 inhibitors  
 
5.1 Evaluation of compound 6 as a lead for novel Sirt2 inhibitors (Paper IV) 
In an initial study, a set of compounds based on the chroman-4-one and chromone scaffolds 
were tested against human Sirt2 to see if these privileged structures could serve as scaffolds 
for sirtuin modulators (data not shown). Interestingly, 8-bromo-6-chloro-2-pentylchroman-
4-one 6 (Figure 28) showed excellent inhibition (88%) of Sirt2 at 200 µM concentration in a 
fluorescence-based assay.149 A more detailed determination of the potency gave an IC50 value 
of 4.5 µM. Compound 6 was also tested against Sirt1 and Sirt3 at 200 µM concentration 
resulting in less than 10% inhibition of these sirtuin subtypes. Initial experiments to 
investigate whether 6 was substrate competitive showed that the chroman-4-one derivative 
acts via non-competitive binding with the substrate (the corresponding NAD+ competitive 
experiments are ongoing). 
 
Figure 28. The 2-alkyl substituted chroman-4-one 6 acts as a selective Sirt2 inhibitor with 88% 
inhibition at 200 µM and an IC50 value of 4.5 µM.  
In collaboration with a research group at the University of Eastern Finland in Kuopio, the 
Sirt2 inhibition was verified with two different methods. First, a western blot analysis of the 
Sirt2-mediated deacetylation of acetylated α-tubulin was carried out and inhibition of the 
Sirt2 catalyzed reaction by 6 was observed (Figure 29A). Secondly, a Sirt2 activity assay based 
on the release of radioactive 14C-nicotinamide was performed in the presence of an 
acetylated peptidic substrate (RSTGGK(Ac)APRKQ) without a fluorophore (Figure 29B). 
In this assay 6 gave 66% inhibition. Taken together, 6 was able to inhibit the deacetylation of 
three different substrates; an artificial substrate with a fluorophore, and a peptide and a 
protein substrate without a fluorophore. Based on these results a series of analogs of 6 was 
synthesized and evaluated as Sirt2 inhibitors. 
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Figure 29. Inhibition of Sirt2 mediated deacetylation reactions by compound 6. (A) Western blot 
analysis of the inhibition of Sirt2 mediated α-tubulin deacetylation by 6. The concentration of 6 
was 200 µM, measurements were done at 30 min and 1 hour. (B) Inhibition by 6 of Sirt2 
mediated deacetylation of the acetylated peptide RSTGGK(Ac)APRKQ. The reaction was 
detected by formation of the reaction product 14C-nicotinamide. 
5.1.1 Synthesis of potential Sirt2 inhibitors based on 6  
An initial structure activity relationship (SAR) study based on 6 was performed. The alcohol 
58, the chroman derivative 59 and the chromen 60 were synthesized (Scheme 16) to 
investigate if the carbonyl group in the chroman-4-one was necessary for Sirt2 inhibition. 
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Scheme 16. Formation of alcohol derivative 58, chroman 59, and chromen 60, respectively. 
Reagents and conditions: (a) NaBH4, MeOH/THF, 0 °C→rt, 15 min; (b) Et3SiH, BF3·Et2O, 
CH2Cl2, -78 °C→rt, 19 h; (c) p-TSA (cat.), MgSO4, toluene, 90 °C, 1.5 h. 
Thereafter, to reveal whether the inhibitory effect of 6 is caused by steric or electrostatic 
properties of the substituents, various substitution patterns in the aromatic ring system of 2-
pentylchroman-4-ones (61-68) were investigated (Scheme 17). In addition, the alkyl length of 
the 2-substituents was modified to three (69) and seven carbons (70). As previously 
described (section 3.1) the synthesis was performed by reacting the appropriate 
acetophenone with an aldehyde in a base promoted aldol condensation using DIPA as a base 
in EtOH under microwave conditions. This resulted in low to good yields (17-71%) of 
products. 
 
 
Scheme 17. Formation of chroman-4-ones 61-70. Reagents and conditions: (a) Appropriate 
aldehyde, DIPA, EtOH, 160-170 °C, 1 h, MW. 
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Also the 2-alkyl substituted chromone 25 and flavone 71150 (Scheme 18) were selected for 
testing for their inhibitory activity of Sirt2.  
 
Scheme 18. The chromones 25 and 71 selected for testing of the inhibitory activity towards Sirt2.  
5.2 Biological evaluation of chroman-4-one and chromone based Sirt2 inhibitors  
Table 7 shows a summary of the results of the synthesized chroman-4-one derivatives when 
tested for their inhibitory activity at Sirt2 in the Fluor-de-Lys assay.79, 149 The assay is based 
on a combination of a fluorescently labeled p53 derived substrate containing an acetylated 
lysine residue (Gln-Pro-Lys- Lys(Ac)) and a developer (trypsin) and involves two main steps: 
first the Sirt2 substrate is incubated with Sirt2 together with NAD+ and inhibitor. 
Deacetylation of the substrate sensitizes the substrate so that in the second step, treatment 
with trypsin produces a fluorophore. The readout is a fluorescence signal (460 nm) which is 
proportional to the amount of deacetylated substrate produced by Sirt2 action.  
 
The IC50 values were measured on derivatives with >70% inhibitory effect at 200 µM. The 
unsaturated analog of 6, chromone 25, was insignificantly less active than 6 with an IC50 
value of 5.5 μM. Interestingly, the difluorinated 63 with smaller but more electronegative 
substituents was considerably less active than the other dihalogenated derivatives (6 and 61) 
but more potent than the unsubstituted 16. This suggests that electron-withdrawing groups 
in general enhance activity but that electrostatic properties are not exclusively responsible for 
strong inhibition. Replacement of the halogens with methyl groups (62) caused a slight 
decrease in activity compared to the chloro- and bromo-substituted 6 but a clear increase in 
activity compared to the difluorinated 63. This supports the previous finding that larger 
substituents in the 6- and 8-positions are necessary to achieve significant inhibition. 
Derivatives 58-60 with no carbonyl present show low inhibition (31-38% at 200 µM), which 
indicates a need of a hydrogen acceptor group in that position. 
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Table 7. The in vitro activity of chroman-4-one/chromone based derivatives against Sirt2. 
 
Cmpd R2 R6 R7 R8 Inhib. 200 µM (%)a IC50 (µM)
b,c
6 (CH2)4CH3 Cl H Br 88 ± 0.9 4.3 (3.5-5.4) 
16 (CH2)4CH3 H H H 4.9 ± 4.8 n.d.
61 (CH2)4CH3 Br H Br 92 ± 1.2 1.5 (1.3-1.7) 
62 (CH2)4CH3 CH3 H CH3 83 ± 0.7 6.2 (4.7-8.1) 
63 (CH2)4CH3 F H F 30 ± 1.3 n.d. 
64 (CH2)4CH3 Cl H H 55 ± 2.4 n.d. 
65 (CH2)4CH3 NO2 H H 58 ± 0.7 n.d. 
66 (CH2)4CH3 OCH3 H H 20 ± 4.1 n.d. 
67 (CH2)4CH3 H H Br 28 ± 1.1 n.d. 
68 (CH2)4CH3 H F H 18 ± 1.0 n.d. 
69 (CH2)2CH3 Cl H Br 76 ± 1.8 10.6 (9.0-12.5) 
70 (CH2)6CH3 Cl H Br 57 ± 2.5 n.d. 
1 CH2CH2Ph Cl H Br 81 ± 0.7 6.8 (5.8-8.0) 
7 CH(CH3)2 Cl H Br 52 ± 1.0 n.d. 
3 CH2CH2(3-indolyl) Cl H Br 53 ± 1.7 n.d. 
5 CH2CH2(N-Ts)(3-indolyl) Cl H Br 27 ± 1.6 n.d. 
25 (CH2)4CH3 Cl H Br 82 ± 0.4 5.5 (4.8-6.2) 
71 Ph Cl H Br 20 ± 1.4 n.d. 
58 (CH2)4CH3 Cl H Br 31 ± 3.0 n.d. 
59 (CH2)4CH3 Cl H Br 38 ± 1.3 n.d. 
60 (CH2)4CH3 Cl H Br 38 ± 1.2 n.d. 
aSD, standard deviation (n = 3). bIC50 (95% confidence interval). IC50 values were determined for compounds 
showing >70% inhibition of Sirt2 at 200 μM concentration. cn.d. = not determined. 
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To probe the importance of the 6- and 8-substituents for inhibitory potency, derivatives 
lacking one of these groups were synthesized (64-67). Compound 64 that only contains the 
6-chloro substituent showed a decrease in activity (55% at 200 µM). No change in activity 
was observed when the 6-chloro substituent was replaced with an electron-withdrawing nitro 
group 65 (58% at 200 µM). Interestingly, with an electron-donating methoxy group in the 
same position (66) the inhibitory activity decreased to 20% at 200 µM. This particular 
example shows that the activity can be altered by the electronic nature of the substituent. 
Compound 67 lacking a substituent in the 6-position was significantly less potent than the 
lead compound 6. Thus, the substituent in the 6-position is more important for activity than 
that in the 8-position.  
 
It was also clarified that electron-rich chroman-4-ones generally are less potent inhibitors 
than electron-poor compounds. The unsubstituted 2-pentylchroman-4-one 16 lost all 
inhibitory activity, indicating that substituents in the aromatic system are necessary to 
achieve any inhibition. One example of substitution in the 7-position was explored with the 
fluorinated 68 which showed only weak inhibitory activity (18% at 200 µM). In summary, 
among the investigated modifications it was found that an alkyl chain with three to five 
carbons in the 2-position, larger, electron-withdrawing groups in the 6- and 8-positions and 
the carbonyl group intact were crucial for high potency. The summary of the SAR is 
illustrated in Figure 30. 
 
 
Figure 30. Results of the SAR study of chroman-4-one based Sirt2 inhibitors.  
5.3 Determination of the absolute configuration of the enantiomers of 6  
The enantiomers of 6 were separated by preparative chiral HPLC. The absolute 
configuration was intended to be determined by means of X-ray crystallography. 
Unfortunately, all attempts to obtain useful crystals of the enantiomers failed. A valid 
alternative for the determination of the absolute configuration of small molecules is to 
compare experimental and calculated vibrational circular dichroism (VCD) spectra.151 To 
predict the VCD spectra of low energy conformers of a molecule, density functional theory 
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(DFT) calculations can be used. Highly flexible groups in a molecule lead to many 
conformers which have to be considered in the calculation of the VCD data. Therefore, to 
facilitate the configurational determination, the calculations were done on a slightly truncated 
structure (2-ethylchroman-4-one instead of 2-pentyl, Figure 31) as the change in the alkyl 
group is not expected to alter the VCD spectra to any greater extent.152 The experimental 
spectra of the two enantiomers of 6 were compared with the calculated spectra of the R- and 
the S-enantiomers of the modified structure.  
 
Figure 31. Structures used for the DFT calculations of VCD spectra to determine the absolute 
configuration of the enantiomers of 6. To simplify the ab initio calculations the 2-pentyl group in 6 
was truncated to an ethyl group. 
As can be seen in the VCD spectra (Figure 32) several bands in the frequency region from 
1500 to 1100 cm-1 show good alignment between the experimental spectrum of (-)-6 and the 
calculated spectrum of the S-enantiomer of the 2-ethyl analog. Equally good alignment in the 
same region is obtained when comparing the experimental spectrum of (+)-6 and the 
calculated spectrum of the R-enantiomer. Thus, from this study it can be concluded that (-)-
6 most likely has the S-configuration and (+)-6 the R-configuration.  
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Figure 32. Comparison of the experimental VCD spectra of (-)-6 (blue) and (+)-6 (green) with 
the calculated spectra of the S-enantiomer (purple) and the R-enantiomer (red) of 8-bromo-6-
chloro-2-ethylchroman-4-one, respectively. 
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The individual enantiomers of the lead compound 6 were tested. It turned out that the 
enantiomers had only slightly different inhibitory activities. The Sirt2 inhibition for the (-)-6, 
and (+)-6 enantiomers showed 91±0.8%, and 70±0.8% inhibition of Sirt2, respectively. The 
(-)-6 enantiomer was a slightly more potent inhibitor with an IC50 value of 1.5 μM (1.3±1.7) 
compared to (+)-6 with an IC50 of 4.5 μM (3.5±5.9).  
5.4. Synthesis of chroman-4-one based Sirt2 inhibitors with more hydrophilic 
substituents in the 2-position (Paper V) 
The previous findings that 2-alkyl substituted chroman-4-ones could act as selective Sirt2 
inhibitors were very interesting, there was however a need to increase the solubility of the 
derivatives prior testing on cells. The intention was to incorporate heterofunctional groups 
such as amines, amides, alcohols, acids or esters in the structures. The substituent in the 2-
position was selected for the desired modifications.  
The initial aim was to synthesize 2-hydroxyalkyl substituted chroman-4-ones with different 
chain lengths (Scheme 19). The synthetic strategy was to construct the chroman-4-one 
framework using the base-mediated method described in section 3.1. The synthetic pathway 
to the appropriate aldehydes started with a mono-protection of the diols 72-74 using NaH 
and tri-butylsilyl chloride (TBSCl) (Scheme 19) according to a procedure reported by 
McDougal et al. which gave 72a-74a.153 A subsequent Swern oxidation gave the 
corresponding aldehydes 72b-74b. Swern oxidations were also performed on a hydroxy-
containing polyethyleneglycol (PEG) derivative 75 to give 75b and three commercially 
available pyridylalcohols 76-78 to afford 76b-78b.  
The chroman-4-one derivatives 72c-78c were prepared from the synthesized aldehydes via 
the base-promoted aldol-condensation followed by oxa-Michael ring closure reaction using 
DIPA as the base. The reaction was run in EtOH under microwave heating at 150-170 °C 
for 1 h. Eventually the TBS group in 72c-74c was removed by treatment with Selectflour® 
in a microwave-assisted reaction furnishing the deprotected chroman-4-ones 72d-74d in 31-
78% yield over three steps.  
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Scheme 19. Synthesis of 72d-74d and 75c-78c. Reagents and conditions: (a) TBDMSCl, NaH, 
THF, 1 h, rt; (b) (COCl)2, DMSO, TEA, THF, -78 °C→rt or Dess-Martin periodinane, CH2Cl2,     
0 °C, 1.5 h; (c) 3’-Bromo-5’-chloro-2’-hydroxyacetophenone, DIPA, EtOH, MW, 170 °C, 1 h; (d) 
Selectfluor®, MeOH, 30 min, 150 °C, MW.  
By using compounds 72d and 73d in a Swern oxidation and a subsequent Pinnick oxidation 
the corresponding carboxylic acids 72e-73e were obtained (Scheme 20). The amide analogs 
72f and 73f-g were then synthesized via activation of the acids with N,N’-
carbonyldiimidazole (CDI) and a subsequent substitution with the appropriate amines. The 
alcohol 72d was mesylated and reacted in a substitution reaction with either morpholine or 
piperidine to give the cyclic amines 72h-i.  
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Scheme 20. Synthesis of acid, amide, and amine functionalized 2-substituents in the chroman-4-
ones. Reagents and conditions: (a) i) Dess-Martin periodinane, CH2Cl2, rt, 45 min, ii) NaClO2, 
NaH2PO4·2H2O, amylene, H2O, THF, 0 °C→rt; (b) appropriate amine, CDI, CH2Cl2, DMF, 0 
°C→rt; c) MsCl, TEA, CH2Cl2, 0 °C, 2 h; d) Morpholine or piperidine, THF, 120-150 °C, 1 h 
MW. 
In addition, the methyl ester 79 (Figure 33) was also included in the study.154  
 
Figure 33. The structure of 79 included in the biological evaluation.  
5.5 Biological evaluation of the inhibitory activity towards Sirt2  
The evaluation of the Sirt2 inhibitory potency of the synthesized derivatives was performed 
in the same fluorescent based Fluor-de-Lys assay as described previously (section 5.2). The 
introduction of alcohols in the 2-position (72d-74d), the PEG moiety (75c), carboxylic acids 
(72e-73e), or the amides (72f, 73f, and 73g) did not improve the inhibition of Sirt2 at 200 
µM in comparison to the lead compound 6 (Table 8). However, for the 3-pyridyl analog 77c 
(86% at 200 µM), the inhibition was comparable with 6 and the phenethyl inhibitor 1. For 
the 2-, and 4-pyridyl moieties (76c and 78c), the inhibition of Sirt2 was somewhat lower (73-
74% at 200 µM). The morpholine and piperidine derivatives 72h-72i were found to be 
activators in the Fluor-de-Lys assay but weak inhibitors in a SIRTainty™ assay.155 From the 
tested compounds the ester analog 79 was the most potent Sirt2 inhibitor at 200 µM with an 
inhibition of 90±0.6% and an IC50 value of 1.9 µM.  
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Table 8. The in vitro activity of chroman-4-ones based derivative against Sirt2. 
 
Comp. R2 
% Inhibition at 
200 Ma 
IC50 (µM)b,c 
1 CH2CH2Ph 81 ± 0.7 6.8 (5.8-8.0) 
6 (CH2)4CH3 88 ± 0.9 4.3 (3.5-5.4) 
72d (CH2)3OH 18 ± 1.1 n.d. 
73d (CH2)4OH 52 ± 0.9 n.d. 
74d (CH2)5OH 69 ± 0.5 n.d. 
75c CH2O(CH2)2OCH3 33 ± 2.0 n.d. 
76c CH2CH2(2-pyridyl) 74 ± 0.5 n.d. 
77c CH2CH2(3-pyridyl) 86 ± 1.9 3.7 (3.1-4.5) 
78c CH2CH2(4-pyridyl) 73 ± 1.8 10.02 (8.3-12.2) 
72e (CH2)2COOH 6.8 ± 0.5 n.d. 
73e (CH2)3COOH 7.6 ± 1.5 n.d. 
72f (CH2)2CONHCH3 4.8 ± 0.2 n.d. 
73f (CH2)3CONHCH(CH3)2 23 ± 1.8 n.d. 
73g (CH2)3CON(CH3)2 53 ± 1.4 n.d. 
72h (CH2)3(1-morpholinyl) 20 ± 10.7d n.d. 
72i (CH2)3(1-piperidyl) 40 ± 2.8d n.d. 
79 (CH2)3COOCH3 90 ± 0.6 1.9 (1.6-2.5) 
aSD, Standard Deviation (n = 3). bIC50 (95% confidence interval). IC50 values were determined for 
compounds showing >70% inhibition of Sirt2 at 200 μM concentration. cn.d. = not determined. dThe 
inhibitory activity was determined in a SIRTainty™ assay.155 
The in vitro activities indicate that hydrogen bond acceptor properties are desirable in the 2-
position. Further testing of analogs including ester isosteres and mono-methyl amide with 
the same length as the corresponding ester 79 are of great interest. Also substituted pyridyl 
analogs and alcohols with longer chain lengths could be valuable.  
5.6 Evaluation of the antiproliferative activity of pyridyl derivatives 77c and 78c  
The 3-pyridyl derivative 77c and the 4-pyridyl analog 78c (Figure 34) were tested for their 
effects in a proliferation/cytotoxicity assay on MCF-7 breast cancer cells and A549 lung 
cancer cells.  
 
Figure 34. The 3- and 4-pyridyl derivatives were selected for antiproliferative/cytotoxicity effects 
on MCF-7 breast cancer cells and A549 lung cancer cells.   
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The protein mass of the living cells was measured using a sulforhodamine B based 
fluorescence assay.90, 156 Interestingly, 77c and 78c showed a significant reduction of the 
proliferation of the two cancer cell lines at 10 and 50 µM (Figure 35). 
 
Figure 35. Results from the MCG-7 breast cancer cells and A549 lung cancer cells cytotoxicity 
assays where 77c and 78c show a significant decrease in the cell proliferations at 10 and 50 µM. 
Further clarification of the mechanism behind the inhibition of the chroman-4-one based 
Sirt2 inhibitors 77c and 78c of the MCG-7 breast cancer cells and the A549 lung cancer cells 
is needed. Preliminary tests of the pyridyl derivatives on HEK cells also showed decreased 
cell proliferation (data not shown) but this finding also needs to be investigated further.  
 
A549 lung cancer MCF‐7 breast cancer 
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6. Proline mediated formation of novel chroman-4-one 
tetrahydropyrimidines 
 
6.1 A proline catalyzed Mannich reaction for the incorporation of a 3-aminomethyl 
group (Paper VI) 
As previously described (section 3.2.2) the introduction of an aminomethyl group in the 3-
position of chroman-4-one was of great interest in our project (Figure 36). Although the 
Mannich reaction using (CH2O)n and CbzNH2 did not result in the desired product this 
reaction was further investigated. Of special interest was the fact that L-proline is known to 
efficiently catalyze asymmetric Mannich reactions, so for the additional studies of this 
reaction L-proline was chosen as the catalyst.157-159  
 
Figure 36. The planned synthetic route to introduce an aminomethyl group in the 3-position of 
2-alkyl substituted chroman-4-one using an L-proline catalyzed Mannich reaction.  
6.2 Formation of tricyclic derivatives 81-83  
Interestingly, when the racemate of 5 was reacted with a catalytic amount of L-proline (0.3 
equiv) and an excess of N-methylenebenzylamine160 (5 equiv) in DMSO at 50 ºC for 48 h 
the novel tricylic derivative 81 was formed in 52% yield (Scheme 21). The chroman-4-one 1 
substituted with a phenethyl group in the 2-position and the chroman-4-one 80161 with a 
considerably smaller 2-methyl substituent were also used as starting materials (Scheme 21). 
Applying the identical reaction conditions, the products 82 and 83 were formed but in lower 
yields (26% and 15%, respectively) as compared to 81. An attempt to synthesize a derivative 
with a 2-phenyl substituent was unsuccessful. 
 
Scheme 21. Formation of novel tricyclic derivatives. Reagents and conditions: (a) N-
methylenebenzylamine, L-proline, DMSO, 50 °C, 48 h. 
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The structure of the tricyclic derivative 81 was confirmed with a crystal structure, where the 
large 2-substituent was shown to be axially positioned (Figure 37). 
 
Figure 37. Crystal structure of tricyclic derivative 81.  
In this reaction, proline is suggested to catalyze the enolization of the chroman-4-one 
(Scheme 22) instead of mediating an enamine formation, which was previously proposed for 
L-proline.159 This conclusion is based on experiments using other secondary amine sources 
such as DIPA and pyrrolidine which were shown to mainly react as nucleophiles leading to 
ring opening of the chroman-4-one ring (according to 1H NMR spectroscopic analysis of the 
crude reaction mixture). In addition, upon heating a mixture of L-proline and chroman-4-
one 5 at 50 °C no enamine formation was observed by 1H NMR spectroscopy. Hence, in the 
proposed mechanism the enols of 1, 5, and 80 attack the preformed N-
methylenebenzylamine providing the Mannich product as an intermediate. The subsequent 
nucleophilic attack of the newly formed amino function on a second N-
methylenebenzylamine gives the aminal of which one amino group attacks the carbonyl 
functionality in the chroman-4-one. Subsequent dehydration provides the 
tetrahydropyrimidine ring and thus the final product. 
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Scheme 22. The proposed mechanism for the formation of the tricyclic derivatives.  
In an attempt to optimize the yield of the tricyclic derivatives 81-83 a series of reaction 
conditions were examined. The use of smaller amounts of N-methylenebenzylamine, shorter 
reactions times or higher temperatures (20 min or 2 h at 80, 120 or 150 ºC under microwave 
irradiation) resulted only in lower conversions. Similar observations were made upon 
variation of the chiral catalysts (sarcosine, L-pipecolic acid), the use of achiral catalysts 
(glycine, DIPA, DIPEA or pyrrolidine), racemic catalyst (D/L-proline) or alteration of 
solvents (THF or DMF). Neither the change of substrate structure by removal of aromatic 
substituents or by introduction of electron donating (OMe) or electron withdrawing (NO2 or 
Cl) groups in the 6-position of the chroman-4-one resulted in improved yields. Further 
attempts on reacting 5 with other electrophiles such as N-methylene p-anisidine imine 
provided only traces of the Mannich product along with numerous impurities. Using 
dibenzyl imine as the electrophile resulted only in recovered starting material. 
The isolated yields of derivatives 81-83 were moderate due to the competing formation of 
additional heterocyclic products. For example, the synthesis of 81 also yielded 81a in 7% 
isolated yield (Scheme 23). As expected the formation of the corresponding products was 
detected in the synthesis of 82-83 which gave 82a-83a in 26% and 23% yield, respectively. 
Compound 81 was found to have identical molecular weight to 81a, but showed a different 
1H NMR spectrum and chromatographic behavior. Therefore additional HMBC and 
NOESY-based NMR spectroscopic investigations were performed, as described in more 
detail below.  
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Scheme 23. Summary of the formation of the tricyclic derivatives of 81-83 and 81a-83a. Reagents 
and conditions: (a) N-methylenebenzylamine, L-proline, DMSO, 50 °C, 48 h.    
The mechanism for the formation of compounds 81a-83a is suggested to occur via a 
nucleophilic attack by benzylamine on the chroman-4-one ring system as shown in Scheme 
24. Benzylamine is most likely formed by partial hydrolysis of N-methylenebenzylamine. 
However, using dry DMSO as the solvent and molecular sieves (4Å) or MgSO4 as drying 
agents did not prevent the decomposition of N-methylenebenzylamine and hence the 
formation of the heterocyclic products 81a-83a.  
 
Scheme 24. A proposed mechanism for the formation of 81a-83a.  
6.3 Conformational analysis of 81 and 81a  
In order to determine the most likely conformations of 81 and 81a in solution a combined 
computational and NMR spectroscopic approach was utilized. A Monte Carlo 
conformational search followed by molecular mechanics calculations was performed using 
the OPLS2005 force field162 as implemented in the MacroModel program.121 Conformations 
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of 81 and 81a within 21 kJ/mol from the global minimum were kept and resulted in two 
distinct conformational families. In addition to the predicted conformations a subsequent 
NMR analysis of molecular flexibility in solution (NAMFIS)163 analysis was performed. 
Distances were determined from nuclear Overhauser enhancement (NOE) spectra. Despite 
the few available protons on 81 and 81a a sufficient number of NOEs were observed for 
description of the orientation of their flexible fragments (Figure 38).  
 
Figure 38. NOE correlations observed in NMR-spectra of 81 and 81a in chloroform.  
Taken together, using the theoretically predicted conformations including dihedral angles in 
combination with NMR derived distances (NOEs) the NAMFIS protocol was used. The 
analysis indicated one preferred conformation of 81 in solution. An overlap between that 
conformation and the solid state X-ray is illustrated in Figure 39a. For 81a the 4-substituent 
is equatorially positioned in solution (Figure 39b). 
                
                                   a)                                                     b) 
Figure 39. a) The solution structure of the core of 81 (yellow) overlapped with its X-ray derived 
conformation (green). b) The solution conformation of the tricyclic core of 81a, as identified by 
NAMFIS analysis. 
As described earlier the use of choman-4-one/chromone scaffolds as novel mimetics of 
bioactive peptides was of great interest (section 4.1). For evaluation of the potential 
applicability of these novel ring systems as peptidomimetics their most stable conformations 
were compared to that of various β-turn conformations of peptides. An initial analysis 
indicated that the tricyclic ring system of 81 could mimic a type VIII β-turn. Hence, 
computer based studies were made on a truncated tricyclic derivative and interestingly the 
tricyclic core of 81 efficiently mimics a native type VIII β-turn (Figure 40). 
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Figure 40. Alignment of a modified structure of the tricyclic derivative 81 and a type VIII β-turn 
( (i+1)=-60°, ψ(i+1)=-30°,  (i+2)=-120° and ψ(i+2)=120°). 
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7. Concluding remarks and future perspective  
 
This thesis describes the use of a scaffold approach for the development of biologically 
active substituted chroman-4-one and chromone derivatives. The thesis also describes 
extensive synthetic work to obtain such compounds, for example the development and use 
of an efficient microwave assisted reaction to facilitate the formation of 2-alkyl substituted 
chroman-4-ones. In addition, developed methods for the incorporation of substituents in 
the 3-position of chroman-4-ones (amine, aminomethyl, bromine, hydroxyl, and cyano) 
provide possibilities for further modifications e.g. via Pd-mediated couplings, alkylations or 
reductive aminations.  
Two biological applications of functionalized chroman-4-one and chromones are described 
in the thesis. In one project, a combination of a computational analysis and affinity studies 
resulted in two naphthyl-containing chroman-4-one and chromone scaffolds, acting as β-
turn mimetics at the somatostatin sst2 and sst4 receptors. The other application covers the 
ability of substituted chroman-4-ones and chromones to be potent and selective Sirt2 
inhibitors with IC50 values in the low µM range. These compounds are considered as a novel 
lead series in the development of Sirt2 inhibitors. To continue the work towards the 
development of potent and selective Sirt2 inhibitors the following aspects should be 
considered:  
 Perform computational modeling in combination with enzymatic kinetic studies to 
investigate the binding site of the chroman-4-one and chromone based Sirt2 
inhibitors.  
 To further improve the physico-chemical properties of the chroman-4-one and 
chromone based Sirt2 inhibitors.  
 To synthesize and evaluate more diverse analogs with regards to the various 
substituents of the chroman-4-one and chromone series and also to develop 
strategies to functionalize related scaffolds.  
 To develop non-peptidic inhibitors of Sirt2 binding to the substrate binding site. 
 To develop synthetic methods to obtain enantioselective chroman-4-one cyclizations. 
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9. Populärvetenskaplig sammanfattning 
 
 
Peptider är involverade i viktiga fysiologiska processer i kroppen såsom reglering av 
blodtryck och smärtsignalöverföring samt kontroll av blodglukosnivåer. Peptider består av 
aminosyror som är sammanlänkade via amidbindningar vilket bidrar till hög vattenlöslighet 
och snabb enzymatisk nedbrytning i kroppen. Peptiders strukturella egenskaper medför en 
stor utmaning vid utvecklingen av peptidbaserade läkemedel. Det finns däremot strategier 
för att förbättra t.ex. stabiliteten hos peptider genom att ersätta amidbindningarna med 
stabila kemiska grupper. Man kallar sådana strukturer för peptidomimetika.  
I den första av två delstudier användes neuropeptiden somatostatin som en modellpeptid där 
den del av peptiden som är viktig för aktiviteten byttes ut mot naturligt förekommande 
grundstrukturer (kromanoner och kromoner). De aminosyror som är viktiga för aktiviteten 
hos somatostatin introducerades på grundstrukturen med olika kemiska metoder. De nya 
föreningarna testades på somatostatinreceptorer och visade samma typ av aktivitet som 
somatostain. Därmed har vi visat att man kan härma somatostatins aktivitet med andra, mer 
stabila substanser. 
I den andra delstudien användes kromanoner och kromoner i ett projekt som behandlar 
enzymet Sirt2. Sirt2 är involverat i olika åldersrelaterade sjukdomar som cancer, diabetes och 
neurodegenererande sjukdomar t. ex. Parkinsons och Alzheimers sjukdom. Enzymets 
specifika funktion är att påverka avläsningen av DNA och att påverka cellcykeln. Därför är 
Sirt2 speciellt intressant inom cancerforskning. Kromanon/kromonderivaten har visat sig 
selektivt kunna hämma Sirt2. Hur bra hämmningen blir är helt beroende på vilka grupper 
som introducerats på kromanon/kromonsystemet. Intressant nog har två syntetiserade 
kromanonbaserade Sirt2-inhibitorer också visats minska tillväxt av bröstcancer- och 
lungcancerceller.  
Genom att använda substituerade kromanoner och kromoner har dessa studier visat att 
substanserna besitter olika effekter beroende på vilka substituenter som bundits till 
grundstrukturerna. Substanserna som inhiberar Sirt2 kan förhoppningsvis bidra till att öka 
förståelsen och kunskapen om enzymets funktion. 
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B. Experimental procedures not included in papers I-VI 
(Z)-3-(Aminomethylene)-8-bromo-6-chloro-2-phenethylchoman-
4-one (Z-36). 8-Bromo-6-chloro-3-cyano-2-phenethylchromone (1c) 
(25 mg, 0.06 mmol) was dissolved in anhydrous THF (2 ml) and cooled 
to -78 ºC. DIBAL-H (0.06 ml, 0.06 mmol, 1 M in CH2Cl2) was added 
dropwise to the reaction mixture. After 1 h at -78 ºC a further portion 
of DIBAL-H (0.06 ml, 0.06 mmol, 1 M in CH2Cl2) was added. After 2 
h the reaction was quenched with NH4Cl (sat., aq.) followed by the addition of EtOAc. The 
aqueous phase was extracted three times with EtOAc and the combined organic phases were 
washed once with H2O and twice with brine. The organic phase was dried over anhydrous 
MgSO4 and the solvent was finally removed under vacuum. Purification by flash 
chromatography using EtOAc:heptane (2:8→4:6) gave Z-36 (17 mg, 66%) as a beige solid. 
Mp 106–108 ºC; 1H NMR (CDCl3) δ 9.26 (br d, J = 10.3 Hz, 1H), 7.82 (d, J = 2.6 Hz, 1H), 
7.63 (d, J = 2.6 Hz, 1H), 7.34–7.17 (m, 5H), 6.86–6.80 (m, 1H), 5.25 (br s, 1H), 4.88 (m, 1H), 
2.88–2.76 (m, 2H), 2.30–2.19 (m, 1H), 1.87–1.77 (m, 1H); 13C NMR (CDCl3) δ 180.7, 153.1, 
147.3, 140.9, 136.5, 128.6, 128.5, 126.7, 126.1, 125.5, 125.2, 112.3, 102.7, 79.0, 37.4, 31.6; 
HRMS (ESI-LC/MS) [M+H]+: Calcd for C18H16BrClNO2: 392.0053 Found: 392.0053. 
2-Pentylchroman-4-one (16). 2-Pentylchroman-4-one 16 was synthesized 
from 2-hydroxyacetophenone (2.00 ml, 16.62 mmol) according to the 
general procedure described in Paper I with the following modifications: 
The reaction was run for 70 min at 170 ºC in a microwave cavity. The 
solvent was evaporated and CH2Cl2 was added prior the work up. The 
crude product was purified by flash chromatography using EtOAc:heptane (5:95) as eluent 
to obtain 16 (1.33 g, 37%) as a pale yellow, viscous liquid. 1H NMR (CDCl3) δ 7.85 (dd, J = 
7.7, 1.7 Hz, 1H), 7.48-7.41 (m, 1H), 7.02-6.91 (m, 2H), 4.49–4.35 (m, 1H), 2.72-2.60 (m, 2H), 
1.94-1.78 (m, 1H), 1.76-1.62 (m, 1H), 1.61-1.18 (m, 6H), 0.90 (t, J = 7.0 Hz, 3H); 13C NMR 
(CDCl3) δ 192.5, 161.6, 135.8, 126.8, 121.0, 120.9, 117.8, 77.8, 42.9, 34.8, 31.5, 24.5, 22.4, 
13.9; Anal. Calcd for C14H18O2: C, 77.03; H, 8.31 Found: C, 77.33; H, 8.40. 
3-Bromo-2-pentylchroman-4-one (16a). 3-Bromo-2-pentylchroman-4-
one 16a was synthesized from 16 (1.21 g, 5.54 mmol) according to the 
general procedure described in Paper I. The purification by flash 
chromatography using toluene:heptane (6:4) gave 16a (1.43 g, 86%) as a 
slightly yellow viscous liquid in a syn:anti ratio of 78:22. 1H NMR (CDCl3) δ 
7.96-7.88 (m, 1H), 7.57-7.48 (m, 1H), 7.12-6.97 (m, 2H), 4.62-4.54 (m, anti, 0.22H), 4.51 (d, J 
= 6.5 Hz, anti, 0.22H), 4.38 (d, J = 1.7 Hz, syn, 0.78H), 4.17-4.11 (m, syn, 0.78H), 2.13-1.99 
(m, syn, 0.78H), 1.92-1.72 (m, syn, anti, 1.22H), 1.64-1.25 (m, 6H), 0.92 (t, J = 7.0 Hz, 3H); 
O
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13C NMR (CDCl3) δ 186.2 (syn), 185.6 (anti), 160.6 (syn), 159.2 (anti), 136.7 (anti), 136.5 (syn), 
128.2 (syn), 127.9 (anti), 122.0 (syn), 121.8 (anti), 118.6 (anti), 118.1 (syn), 118.0 (anti), 117.8 
(syn), 81.7 (anti), 78.4 (syn), 50.7 (syn), 50.1 (anti), 32.6 (syn), 31.8 (anti), 31.4 (syn), 31.2 (anti), 
24.7 (anti), 24.1 (syn), 22.40 (anti), 22.36 (anti), 13.9 (syn, anti); HRMS (ESI-LC/MS) [M+H]+: 
Calcd for C14H18BrO2: 297.0490 Found: 297.0505. 
3-Cyano-2-pentylchroman-4-one (16c). 3-Cyano-2-pentylchroman-4-one 
16c was synthesized from 16b (0.62 g, 2.10 mmol) according to procedures 
described in Papers I and II. Purification by flash chromatography using 
EtOAc:heptane (1:9) gave 16c (0.38 g, 75%) in a syn:anti ratio of 18:82 as a 
colorless oil that crystallized over time. 1H NMR δ 7.95-7.89 (m, 1H), 7.61-
7.53 (m, 1H), 7.14-7.00 (m, 2H), 4.59-4.47 (m, syn, anti, 1H), 3.85 (d, J = 12.0 Hz, anti, 
0.82H), 3.71 (d, J = 3.1 Hz, syn, 0.18H), 2.18-1.92 (m, syn, anti, 1.82H), 1.91-1.79 (m, syn, 
0.18H), 1.77-1.29 (m, 6H), 0.97-0.88 (m, 3H); 13C-NMR δ 182.9 (anti), 182.3 (syn), 160.8 
(anti), 160.7 (syn), 137.5 (syn), 137.2 (anti), 128.0 (syn), 127.8 (anti), 122.5 (anti), 122.4 (syn), 
118.9 (anti), 118.8 (syn), 118.3 (syn), 118.0 (anti), 113.6 (anti), 113.0 (syn), 78.5 (anti), 77.6 (syn), 
45.0 (anti), 43.1 (syn), 33.6 (anti), 31.8 (syn), 31.3 (anti), 31.2 (syn), 24.6 (syn), 24.0 (anti), 22.44 
(anti), 22.39 (syn), 13.94 (anti), 13.89 (syn); HRMS (FT-ICR-MS) [M+H]+: Calcd for 
C15H18NO2: 244.1338 Found: 244.1345. 
3-tert-Butoxycarbonylaminomethyl-4-hydroxy-2-pentylchroman 
(37). A solution of 16c (50 mg, 0.2 mmol) in EtOH (99.5%, 10 ml) was 
hydrogenated using an H-Cube® apparatus (1 ml/min, 10% Pd/C) 
under 30 bar at 20 °C. The reaction mixture was concentrated under 
reduced pressure and the alcohol derivative was obtained in 
quantitative yield according to 1H NMR spectroscopy on the crude product. The crude 
product (38 g, 0.15 mmol) was dissolved in MeOH/THF (1:1, 2.5 mL) and hydrogenated (1 
ml/min, Raney Ni) under 10 bar at 25 °C. The solvent was removed by reduced pressure 
and the crude primary amine was directly used in next synthesis step without further 
purification. To a stirred solution of the primary amine (33 mg, 0.13 mmol) in THF (10 ml) 
TEA (22 µl, 0.16 mmol) and di-tert-butyl dicarbonate (35 mg, 0.16 mmol) were added. The 
reaction mixture was stirred for 20 h at ambient temperature. The solvent was evaporated 
and water and EtOAc were added. The aqueous phase was extracted five times with EtOAc 
and the combined organic phases were washed three times with H2O and brine. Finally, the 
organic phase was dried over MgSO4, filtered and evaporated to afford the Boc-protected 
amine as a slightly yellow solid. Purification by flash chromatography using 10% 
EtOAc:hexane gave pure 37 (30 mg, 41% over three steps) as a single isomer and as a white 
solid. 1H NMR δ 7.52 (d, J = 7.9 Hz, 1H), 7.10 (t, J = 7.9 Hz, 1H), 7.59 (t, J = 7.5 Hz, 1H), 
6.72 (d, J = 8.2 Hz, 1H), 5.03-4.93 (m, 1H), 4.88-4.79 (m, 1H), 4.59 (d, J = 10.3 Hz, 1H), 
O
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4.23-4.15 (m, 1H), 3.76-3.61 (m, 1H), 3.35-3.25 (m, 1H), 2.14-2.04 (m, 1H), 1.97-1.85 (m, 
1H), 1.45-1.29 (m, 5H), 1.18 (s, 9H), 0.95–0.87 (m, 3H); 13C NMR δ 157.2, 154.1, 128.3, 
127.9, 125.9, 121.1, 115.8, 79.9, 77.7, 66.6, 41.5, 35.3, 32.4, 31.6, 28.1, 25.6, 22.6, 14.0; HRMS 
(ESI-LC/MS) [M+H]+: Calcd for C20H32NO4: 350.2331 Found: 350.2330. 
3-tert-Butoxycarbonylaminomethyl-2-pentylchroman-4-one (38). 
Hydroxychroman 37 (25 mg, 0.08 mmol) was dissolved in CH2Cl2 (4 
ml). The solution was transferred to a vial with activated molecular 
sieves (0.1 g, 3 A). Acetonitrile (0.4 ml, 10%) and N-methyl 
morpholine N-oxide (13 mg, 0.11 mmol) were added followed by 
TPAP (5 mg, 0.01 mmol, 20 mol%). The black reaction mixture was 
stirred at 25 °C for 6 h. The solvent was removed under reduced pressure. The residue was 
dissolved in CH2Cl2 and the suspension was filtered through Celite. The solvent was 
removed under reduced pressure. Purification by flash chromatography using 10% 
EtOAc:hexane gave 38 (17 mg, 68%) as a yellow oil in a syn:anti ratio of 75:25. 1H NMR δ 
7.87-7.81 (m, 1H), 7.52-7.44 (m, 1H), 7.05-6.92 (m, 2H), 5.18-5.02 (m, anti, 0.25H), 5.01-4.88 
(m,, syn, 0.75H), 4.60-4.49 (m, 1.5H), 4.41-4.30 (m, anti, 0.25H), 3.76-3.39 (m, 2H), 3.30-3.17 
(m, 1H), 2.97-2.85 (m, 1H), 2.78-2.66 (m, 0.25H), 2.06-1.73 (m, 2H), 1.70-1.17 (m, 13H), 
0.97-0.78 (m, 3H); 13C NMR δ 194.7, 161.1, 160.5, 155.9, 155.8, 155.8, 136.3, 136.2, 127.0, 
126.9, 121.2, 121.1, 120.4, 120.2, 118.0, 117.9, 79.6, 79.5, 79.3, 50.6, 49.8, 37.0, 36.4, 32.4, 
31.4, 31.3, 29.7, 29.6, 28.3, 25.3, 24.3, 22.6, 22.4, 14.0, 13.9; HRMS (ESI-LC/MS) [M+H]+: 
Calcd for C20H30NO4: 348.2175 Found: 348.2175. 
Methyl 3-(3-acetyl-5-bromo-hydroxyphenyl)-2-
(benzyloxycarbonylamino)propanoate (42). NBS (0.17 g, 0.96 mmol) 
was dissolved in MeCN (2 mL) and cooled to 0 °C. Compound 41 (0.36 
g, 0.96 mmol) was dissolved in MeCN (6 mL) and was added to the NBS 
solution. The mixture was allowed to reach rt and was stirred overnight. The reaction was 
quenched with water and EtOAc. The phases were separated and the organic phase was 
washed with water and brine, dried over MgSO4, filtered and the solvent was finally removed 
under vacuum. Purification by flash chromatography 15→20% EtOAc:toluene gave 42 (0.36 
g, 82%) as a white solid. Mp 151-152 °C; 1H NMR δ 12.8 (s, 1H), 7.50 (d, J = 2.0 Hz, 1H), 
7.45 (bs, 1H), 7.39-7.27 (m, 5H), 5.39 (br d, J = 8.0 Hz, 1H), 5.14 (d, J = 12.2 Hz, 1H), 5.04 
(d, J = 12.2 Hz, 1H), 4.64 (q, J = 6.6 Hz, 1H), 3.75 (s, 3H), 3.13 (dd, J = 5.5, 14.1 Hz, 1H), 
2.98 (dd, J = 6.5, 14.1 Hz, 1H), 2.53 (s, 3H); 13C NMR δ 204.0, 171.5, 157.9, 155.5, 140.2, 
135.9, 130.4, 128.5, 128.3, 128.0, 127.3, 120.1, 111.9, 67.1, 54.6, 52.5, 37.1, 26.6; HRMS (Q-
TOF-MS) [M+2K+H]+: Calcd for C20H21BrK2NO6: 527.9826 Found: 528.1637. 
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Methyl 2-benzyloxycarbonylamino-3-(8-bromo-4-oxo-2-
phenethylchroman-6-yl)propanoate (43). Compound 42 
(0.10 g, 0,23 mmol), 3-phenylpropanal (33 mg, 0.25 mmol) and 
DIPA (0.025 g, 35 uL, 0.25 mmol) in MeOH (2.5 mL) were 
mixed according to the procedure described in Paper I. 
Purification by flash chromatography 10→40% EtOAc:heptane gave 43 (92 mg, 72%) as a 
yellow oil. 1H NMR δ 7.58 (t, J = 2.4 Hz, 1H), 7.53 (s, 1H), 7.42-7.24 (m, 9H), 7.24-7.18 (m, 
1H), 5.33 (br d, J = 7.7 Hz, 1H), 5.17-5.04 (m, 2H), 4.62 (q, J = 5.9 Hz, 1H), 4.49-4.38 (m, 
1H), 3.75 (s, 3H), 3.18-2.85 (m, 4H), 2.78-2.61 (m, 2H), 2.35-2.19 (m, 1H), 2.06-1.85 (m, 
1H); 13C NMR δ 191.2, 171.5, 156.9, 140.6, 128.6, 128.5, 128.2, 128.0, 126.2, 121.9, 77.2, 
67.1, 52.6, 42.6, 36.4, 30.9; HRMS (Q-TOF-MS) [M-CO2Me+H2O]: Calcd for 
C27H28BrNO5: 525.1151 Found: 525.1210. 
